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Interplay of Il-4, Il-21, and Ifnγ
Ifn on Memory B Cell Fate Decisions
Abstract
The ability to establish a durable pool of memory B (BMEM) cells is not only a key feature of adaptive
immunity but also critical for host survival upon secondary infection. Depending on the nature of the
pathogen, preimmune B cells differentiate into various BMEM cells associated with a particular
immunoglobulin isotype. Moreover, cytokines dictate this process via the induction of transcription
factors resulting in a stable lineage. Recently, the transcription factor, T-BET, has been implicated in
reinforcing BMEM cells of the IgG2c isotype. Further, phenotypically similar cells express the integrin,
CD11c, and appear in humoral autoimmunity and aged mice. However, the activation requisites and
extrinsic cues driving T-BET and CD11c expression remain poorly defined. T follicular helper (TFH) cells
instruct B cells to adopt various BMEM cell fates via the production of cytokines—specifically IL-4, IL-21
and IFNγ. Here we reveal a novel interplay among these cytokines in determining T-BET+ B cell fate. We
find that IL-21 or IFNγ directly promote T-BET+ B cells in the context of TLR engagement. Further, IL-4
antagonizes IL-21-induced T-BET expression, but augments that of IFNγ. Finally, IL-21, but not IFNγ,
promotes CD11c expression. Using well-defined infections that drive IL-21 and robust IFNγ or IL-4
production, we show that these same cytokine interactions function in vivo to determine T-BET and CD11c
expression. We elaborate a model in which abundant IFNγ will drive T-BET+ B cells; however, in the
absence of IFNγ, IL-21 and IL-4 reciprocally regulate both T-BET and CD11c. Importantly, CD11c
expression is restricted to BMEM cells, which phenotypically resemble Age-associated B cells (ABCs). In
accord with our infection results, we show that T-BET+CD11c+ ABCs are likely a pool BMEM cells.
Consistent with this idea, ABCs are somatically mutated, class- switched, and require the ability to present
antigen and receive costimulation to form. These findings suggest that T-BET+ B cells seen in health and
autoimmunity share the common initiating features of TLR driven activation within this circumscribed
cytokine milieu.
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ABSTRACT
INTERPLAY OF IL-4, IL-21, AND IFNγ ON MEMORY B CELL FATE
DECISIONS
MARTIN SOUREN NARADIKIAN
MICHAEL PAUL CANCRO
The ability to establish a durable pool of memory B (BMEM) cells is not only
a key feature of adaptive immunity but also critical for host survival upon
secondary infection. Depending on the nature of the pathogen, preimmune B
cells differentiate into various BMEM cells associated with a particular
immunoglobulin isotype.

Moreover, cytokines dictate this process via the

induction of transcription factors resulting in a stable lineage.

Recently, the

transcription factor, T-BET, has been implicated in reinforcing BMEM cells of the
IgG2c isotype. Further, phenotypically similar cells express the integrin, CD11c,
and appear in humoral autoimmunity and aged mice. However, the activation
requisites and extrinsic cues driving T-BET and CD11c expression remain poorly
defined. T follicular helper (TFH) cells instruct B cells to adopt various BMEM cell
fates via the production of cytokines—specifically IL-4, IL-21 and IFNγ. Here we
reveal a novel interplay among these cytokines in determining T-BET+ B cell fate.
We find that IL-21 or IFNγ directly promote T-BET+ B cells in the context of TLR
engagement.

Further, IL-4 antagonizes IL-21-induced T-BET expression, but

augments that of IFNγ. Finally, IL-21, but not IFNγ, promotes CD11c expression.
Using well-defined infections that drive IL-21 and robust IFNγ or IL-4 production,
we show that these same cytokine interactions function in vivo to determine Tiv

BET and CD11c expression. We elaborate a model in which abundant IFNγ will
drive T-BET+ B cells; however, in the absence of IFNγ, IL-21 and IL-4 reciprocally
regulate both T-BET and CD11c. Importantly, CD11c expression is restricted to
BMEM cells, which phenotypically resemble Age-associated B cells (ABCs). In
accord with our infection results, we show that TBET+CD11c+ ABCs are likely a
pool BMEM cells. Consistent with this idea, ABCs are somatically mutated, classswitched, and require the ability to present antigen and receive costimulation to
form. These findings suggest that TBET+ B cells seen in health and autoimmunity
share the common initiating features of TLR driven activation within this
circumscribed cytokine milieu.
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1. OVERVIEW OF HUMORAL IMMUNITY
1.1 The innate and adaptive immune response
Protective immunity relies on establishing appropriate immune effector
functions during primary responses, then sustaining these qualities in effector
and memory cell pools. While appropriate effector functions promote lifelong
immunity, aberrant effector choices can yield failed pathogen clearance, chronic
inflammation, or autoimmunity. Current ideas suggest that cooperation between
the innate and adaptive immune systems rids the vertebrate host of pathogens
while maintaining tolerance to self. Indeed, cells in these two branches establish
a complex network of activating and regulatory interactions that includes both
cell-to-cell contacts and extracellular signals.

Myeloid cells including DCs,

eosinophils, basophils, neutrophils, MΦs, mast cells, comprise the innate system
and are considered the rapid, first line of defense against tissue-invading
pathogens. Further, myeloid cells express germline-encoded PRRs imparting
recognition of and specificity for evolutionarily conserved PAMPs (1).
Importantly, although PAMPs are typically associated with microbes, mammalian
cellular products can also trigger PRRs. Regardless of the source of PAMPs,
engagement with PRRs communicates activation signals. Once initiated, these
responses foster differentiative programs that direct particular effector choices for
the subsequent activation and regulation of the adaptive immune response (2, 3).
In contrast to innate lineages, two lymphoid lineages, T and B cells, are
the primary mediators of adaptive immune responses. Each builds a unique
antigen receptor (TCRs and BCRs, respectively) via a process of gene
1

rearrangement.

In accord with the clonal selection paradigm (4), these

somatically generated receptors are clonally distributed among lymphocytes such
that each T and B cell expresses only one antigen receptor specificity.
Moreover, receptor engagement beyond a requisite threshold affords specificity
and triggers robust intracellular signaling cascades.

Once activated,

lymphocytes possess the unique capacity to generate long-term memory cells of
related pathogen-reactive clones, which often impart protection against
secondary infection. Importantly, lymphocytes accomplish their effector functions
while also maintaining tolerance to the host. Thus, the tenets of the adaptive
immune system–specificity, inducibility, memory, and tolerance—are key aspects
of cell-mediated and humoral immunity as established by T and B cells,
respectively.
In order to orchestrate cell-mediated immunity, T cells recognize antigenic
peptides presented on MHC molecules via the TCR. The coreceptors, CD4 and
CD8, define two functionally distinct subsets of T cells that engage antigen in the
context of MHCII and MHCI molecules, respectively. CD8 T cells, or CTL, are
responsible for lysing cells that present non-self peptides in the context of MHCI
on their surface.

Further, nearly every nucleated cell expresses MHCI

molecules, which are loaded with peptide via the cytosolic pathway, thus allowing
for broad surveillance of intracellular protein synthesis. Conversely, CD4 T cells,
or helper T cells, generally orchestrate immune responses by recognizing nonself peptides in the context of MHCII on the surface of APCs such as DCs, B
cells, or MΦs.

Importantly, CD4 T cells monitor extracellular proteins since
2

MHCII expression is restricted to phagocytic cell types and peptide loading
occurs via the endocytic pathway. Furthermore, helper T cells have the capacity
to differentiate into several effector subsets: TH1, TH2, TH17, TFH, or Treg (5-8).
The cues guiding these cell fate decisions likely involve the nature of the
pathogen, the PAMPs it carries, and how innate and adaptive cells integrate PRR
signals. Further, master transcriptional regulators that reinforce particular fates
frequently characterize these effector differentiation patterns. Thus, preimmune
CD4 T helper cells adopt alternative effector fates based on TCR signal strength,
costimulatory cues, and cytokine milieu (9-12).
Analogously, B cells can adopt a variety of distinct effector fates that are
similarly guided by BCR signal strength coupled with additional cues that foster
key transcriptional programs to establish humoral immunity. Importantly, B cells
also express certain PRRs and respond to PAMPs.

Coupled with the BCR,

integration of these signals ultimately drives antibody production, antigen
presentation and costimulatory interactions with CD4 T cells, and cytokine
secretion.

Principally among these functions, the Ig produced consists of

identical sets of heavy and light chains joined together by disulfide bonds. Both
chains combine to form the antigen binding or CDR, whereas only the heavy
chain forms the Fc region which imparts antibody effector functions. Five main
heavy chain isotypes, µ, δ, γ, ε, and α, combine with either a λ or κ light chain to
make an IgM, IgD, IgG, IgE, or IgA respectively. Moreover, the IgG isotypes can
be subdivided into IgG1, IgG2a/c (IgG2a for BALB/c and IgG2c for C57BL/6, (13)),
IgG2b, or IgG3. Similar to cell fate decisions in T helper cells, B cells adopt an
3

isotype based on the prevailing cytokine meilieu and subsequently induced
master transcriptional regulator. The nature, levels, and persistence of Ig heavy
chain isotypes that are provoked have profound implications for response quality.
Indeed, nearly all heavy chain isotypes link adaptive humoral responses with a
circumscribed group of innate inflammatory cells and systems important for
pathogen clearance, such as complement fixation, opsonization, degranulation,
and ADCC. These effector processes rely on isotype-specific Fc receptors that
are differentially distributed among innate, myeloid, and other cell types. Since
FcR can be either activating or inhibitory, Ig isotype engagement can either
enhance or limit the activation and behavior of these cells (14). While marshaling
these FcR effector systems is critical to effective humoral immunity, the same
effector mechanisms mediate autoimmune and chronic inflammatory pathologies.
Thus, the importance of these Ig:FcR interactions are apparent, yet to generate a
protective antibody of the proper effector isotype requires strict regulation of B
cell development, homeostasis, and activation.
1.2 B lymphocyte commitment, development, and homeostasis
B cells can be separated into two lineages: B-1 and B-2. Debate remains
as to whether B-1 and B-2 cells derive from a common progenitor and diverge
based on antigen-driven selection, or instead reflect the products of distinct,
lineage-restricted progenitors (15-17). Regardless of their exact origins, each
lineage plays distinct yet overlapping roles in humoral immunity, reflecting
differences in their generation, antigen receptor diversity, and anatomic niche.
Murine B-1 cells are derived primarily from the fetal liver, and are sustained
4

largely by self-renewal in the periphery (15, 16, 18, 19). In contrast, continuous
B-2 cell production yields a much larger steady-state pool throughout life (20). B2 cell subsets are defined by surface marker criteria that are correlated with
developmental stage, activation status, recirculation properties, and anatomic
locale.

Table 1 summarizes these criteria, features, and transcriptional

regulators for developing and preimmune B cell subsets. In healthy adults, B
cells are generated continuously from hematopoietic stem cells in the bone
marrow (BM), where Ig heavy and light chain gene rearrangements are
completed during the pro- and pre-B cell stages respectively (21) (reviewed in
(22, 23)). Commitment to the B lineage involves both the acquisition of a B cell
transcriptional program and the suppression of programs leading to other
hematopoietic fates (24). Accordingly, adoption of B lineage fate involves the
expression of PAX5 (25-27), EBF1 (28-31), and E2A proteins (32, 33), which
establish a transcriptional circuit that not only induces and reinforces B lineage
genes, but also represses transcription factors driving alternate lineages (34).
Upon acquisition of surface IgM, developing B cells enter the IMM subset. These
cells migrate to the periphery via the blood and pass through the TR
developmental stages before entering the comparatively long-lived mature FO or
MZ B cell pools (35-40). The cues required to adopt the MZ instead of FO B cell
fate include tonic BCR signal strength and transcriptional programs driven by
Notch2 (41) interactions with Delta-Like-1 (42, 43) reviewed in (44).
Stringent selection based on BCR specificity occurs during both the IMM
and TR stages: only 10% of IMM cells produced survive to exit the marrow, and
5

Table I: Features of developing and preimmune B cell subsets

Locale

B
cell
subset

Surface phenotype
+

+

pro-B
pre-B

CD19 , CD43 , CD93 ,
IgM , IgD

IMM

CD19 , CD93 , IgM ,
lo/IgD

+

BM

-

+

Blood,
lymph,
spleen

TR

FO

MZ

+

-

-

GC
(DZ)
GC
(LZ)

CD19 , IgM , IgD ,
+
+
+
CD23 , PNA , CD95 ,
+
CXCR4 , CD83

SLPC

CD19 , B220 , IgM ,
hi
IgD , CD138

LLPC

CD19 , B220 , IgM ,
hi
IgD , CD138

+

-

+

IgM
Bmem

-

-

IL7

none

?

BR3/TACI

?

TACI/BR3

BLyS

TACI/BR3

BLyS

TACI/BR3

BLyS

BR3

BLyS

BR3

BLyS

TACI/
BCMA

APRIL?
BLyS?
IL6

BCMA

APRIL?

BR3

?

BR3

?

BR3/TACI

?

PAX5

Notch targets

BCL6

BLIMP1
BLIMP1

-

-

none

PAX5

+/-

CD19 , IgM , IgD ,
+
+/CD38 , PDL2 ,
+/+/CD73 , CD80
+
+
CD19 , IgM , IgD ,
+
+/CD38 , PDL2 ,
+/+/CD73 , CD80
+

ABC

-

-

Survival
cytokine

BCL6

+

-

Sw
Bmem

Spleen.
Blood,
BM,
Tissue

-

BLyS
receptors

PAX5
PAX5

CD19 , IgM , IgD ,
+
+
PNA , CD95 ,
+
CXCR4 , CD83

+

Spleen
Blood,
BM

hi

CD19 , CD93 , CD43 ,
hi
lo/IgM , IgD , CD21 ,
CD23
+
CD19 , CD93 , CD43 ,
lo
hi
lo
IgM , IgD , CD21 ,
+
CD23
+
CD19 , CD93 , CD43 ,
hi
lo
+
IgM , IgD , CD21 ,
lo
CD23
+

Lymph
nodes,
Spleen

+

+

+

Spleen/
Blood

+

CD19 , CD43 , CD93 ,
IgM , IgD

Transcription
Factors
PAX5

?

?

-

CD19 , CD93 , CD43 ,
+/+/IgM , IgD , CD21 ,
+/CD23 , CD11c

6

T-BET

only 30% of the TR cells thus generated survive to join the FO or MZ pools (36).
These profound cell losses reflect both negative and positive selection based on
BCR signal strength (45-51), presumably reducing the frequency of polyreactive
and self-reactive specificities (46, 48, 52), as well as selecting for cells with
optimal sub-threshold signal strength (47, 51, 53, 54). Indeed, multiple studies
now indicate that the representation of frankly autoreactive B cell specificities in
each pool decreases at each successive differentiation stage (55, 56). Thus,
among peripheral B cells, the TR pool is a rich source of autoreactive BCR
specificities compared to most other B cell subsets (57).
The steady-state sizes of preimmune FO and MZ B cell pools are
controlled by the TNF family member, B cell activating factor (BAFF) (58, 59)
(reviewed in (60)). This cytokine sustains FO and MZ B cell survival by signals
delivered through BAFF receptor (BAFFR) (61-65). All TR, FO, MZ B cells
express BAFFR (66, 67) and compete continuously for BAFF to survive, such
that available systemic BAFF determines their lifespan and thus overall FO and
MZ pool sizes ((62, 63), reviewed in (68)). Because the steady-state size of preimmune B cell pools is driven by the need for adequate surveillance and hence
organismal size, the idea that BAFF governs this parameter predicts that total
systemic BAFF must be relatively constant and that the predominant source must
be tied to organism volume. Indeed, bone marrow radiation chimeras revealed
that a radioresistant, non-hematopoietic sources of BAFF fully supported primary
B cell homeostasis (69). More recent studies suggest that fibroblastic reticular
cells are the primary source of system BAFF (70).
7

These observations

strengthen the idea that systemic BAFF levels are a surrogate for biological
space, since BAFF is produced by cells whose numbers will scale with organism
size. Thus, BAFF depletion yields profoundly reduced TR, FO, and MZ B cell
numbers, yet spares developing bone marrow B cell subsets. Further, the
stringency of BCR-mediated selection among TR B cells is governed by BAFF;
increasing BAFF lets TR B cells normally lost to negative selection survive (56,
71, 72). Together, these observations favored the notion that systemic BAFF
governs pre-immune B cell numbers by controlling TR cell throughput and
mature B cell survival, thereby acting as the molecular surrogate for homeostatic
‘space’ in the pre-immune B cell niche (68).
1.3 Thymus dependent and independent B cell activation
Among mature primary B cells, BCR ligation initiates downstream
signaling systems that foster activation. The type of antigen, the participating B
cell subset, the avidity of BCR cross linking, and the intercellular interactions
involved dictate the characteristics of the subsequent humoral immune response.
In general, B cell responses follow the two signal paradigm (73), whereby BCR
ligation (signal one) must be followed by additional activation and differentiation
cues (signal 2) that are delivered via other cells or molecules.

Two broad

categories of humoral responses are defined based on the source of second
signals. The thymus-dependent (TD) response involves second signals that are
delivered when B cells internalize, process, and present protein antigens to CD4
helper T cells.

In contrast, the second signals in thymus-independent (TI)

responses are delivered through innate immune receptors such as TLRs
8

expressed by the B cells themselves (TI-1), or through exceptionally intense BCR
cross linking alone (TI-2).
Important differences between TD and TI responses include the naïve B
cell populations that participate, the antibody isotypes generated, the response
duration, the ultimate antibody affinity, and the extent of immunological memory
established. In general, B-2 cells, particularly those in the FO compartment, are
the major contributors to TD responses. In contrast, TI responses arise primarily
from either B-1 cells or the B-2 lineage MZ subset (74). These differences likely
reflect the BCR signaling characteristics and differentiative potential of these
pools, as well as the nature of inducing signals.

TI responses are of short

duration and tend to be skewed towards IgM production, whereas TD responses
are more protracted and will usually culminate in IgG.

Within days after TI

antigen challenge, substantial numbers of antibody secreting plasma cells (PCs)
appear in the splenic extrafollicular regions (75, 76). The antibodies made by
this extrafollicular response are largely IgM, and display comparatively low
affinity for antigen. Conversely, TD responses display a gradual but profound
increase in average antibody affinity – a process termed affinity maturation (77).
Moreover, both types of responses can generate relatively long-lived antibody
forming cells and memory B cells (78-81). As with TI responses, within days of
TD antigen challenge, substantial numbers of PCs that generate low-affinity IgM
appear in splenic extrafollicular regions. However, a few days later clusters of
proliferating B cells appear at the borders of B cell follicles and T cell zones in the
lymph nodes and spleen (82, 83). These are germinal centers (GCs), transient
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structures wherein the unique functional features of TD responses emerge,
including affinity maturation (84, 85), as well as efficient long-lived plasma cell
generation (LLPC) (86).
GC formation requires a series of cognate, bi-directional interactions
between activated CD4 T cells and activated and antigen-presenting B cells
beyond the initial T cell priming event with a dendritic cell (87, 88). These include
MHCII-restricted presentation by the B cell, costimulation via CD40-CD40L, and
key cytokines. Together, these interactions result in the adoption of a GC B cell
transcriptional program driven largely by Bcl-6 (89-92). A key gene upregulated
in GC B cells is activation-induced deaminase (AID), which creates point
mutations in Ig V regions (93, 94). This so-called somatic hypermutation (SHM)
mechanism results in clonal variants of GC B cells with altered antigen affinity
and specificity (95). Through selective competition and survival, clonal variants
with higher affinity for antigen are preserved, whereas those with lower affinity
are at a disadvantage and die (96). While these processes are thought to occur
most efficiently and frequently in GCs, affinity maturation and class-switch
recombination (CSR) in extrafollicular sites have been reported (97, 98). The
details surrounding this preferential survival remain an area of intense
investigation, but clearly involve competition for antigen and subsequently
presenting said antigen (99).

Currently popular models posit that the

anatomically defined GC light zones are where competition for antigen and T
helper cell survival factors and instructive cues occur; whereas proliferation and
AID-mediated SHM occur in GC dark zones (100). Importantly, the CD4 helper T
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cell subset responsible for proper GC reactions is transcriptionally and
anatomically distinct from other T helper lineages (101).

As the moniker

suggests, T follicular helper (TFH) cells migrate to the B cell follicle via CXCR5
(102), select high affinity GC clones into effector pools via BLyS secretion (103)
and direct immunoglobulin isotype determination.
1.4 Activated B cells differentiate into discrete effector subsets
Circulating antibodies have biological half-lives in the range of days to
weeks depending on heavy chain isotype; thus, long term protective immunity
must rely on either LLPCs that persist indefinitely without seeding from BMEM
(104-106), or upon the sustained generation of SLPCs from BMEM precursors
driven by persistent antigen. To adopt activated and effector fates, preimmune B
cells must integrate instructional cues from a variety of signals, sustain the
mutational stress of CSR and SHM, and undergo profound morphological
changes to produce antibody. To support these functions, activated B cells
undergo significant transcriptional reprogramming based on the cues they
receive. Though initially thought to be required for PC commitment (107), the
transcription factor BLIMP1 is necessary for bona fide PC differentiation (108).
Given that PCs bear little morphological resemblance to their clonal progenitors,
they are transcriptionally distinct because BLIMP1 extinguishes the B lineage
determining transcription factor PAX5 (109, 110). In this regard, these cross
competing transcription factors facilitate a gene expression program to direct
mature B cells through activation, selection, and terminal effector function. No
master regulator of the BMEM cell lineage is yet identified; however, T-BET and
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RORα associate with IgG2a/c and IgA isotypes, respectively, are indeed critical for
the formation and maintenance of some BMEM subsets (111).
The homeostatic regulation of antigen experienced B lineage pools is less
well understood, and likely involves a more complex set of players than the
comprehensive role assumed by BLyS for preimmune pools. Indeed, the
heterogeneity in lifespan and composition of BMEM and PC subsets has only
begun to be appreciated over the last several years, and will likely expand
further. For example, recent conceptual advances challenge the notion that PCs
are a monolithic population. Instead, T cell independent PCs are longer lived
than previously thought (81); new subset markers have revealed phenotypic
heterogeneity and complex turnover kinetics in BM PC pools (112, 113); and
some PCs secrete cytokines and antimicrobial agents in addition to antibodies
(114). Despite this growing complexity, several factors that govern PC longevity
and homeostasis have nonetheless been identified. LLPC survival depends, at
least in part, on BAFF and/or APRIL signaling via the BCMA and/or TACI
receptors (115, 116). In this regard, LLPCs are thought to occupy survival niches
independent of the primary pool. Homing to and occupation of these longevityfostering niches is still an active area of research especially given newly
discovered subsets and isotype-associated functional differences (117).
Similarly, several BMEM subsets have been defined, based on the
presence of different isotypes and further markers (Table 1). The immunological
role of BMEM cells may appear ostensibly redundant with simultaneous, clonally
similar, and elevated antibody titers; however, recent evidence highlights a
12

distinct BMEM cell role in response to pathogenic variants that have escaped the
neutralizing capacity of the primary antibody response (118).

Moreover,

delineating which BMEM subsets rapidly differentiate into PCs or engage in further
GC formation upon secondary antigen challenge is an area of intense
investigation. While some evidence suggests that isotype determines BMEM cell
subset and properties (119, 120), more recent work shows that surface markers
such as PD-L2 and CD80 predict functional outcomes irrespective of isotype
(121). Furthermore, the maintenance of these pools is independent of BAFF,
antigen, or T cells (122-124). In toto, these observations indicate that PCs and
BMEM cells play non-redundant roles in immunity and occupy distinct homeostatic
niches.
1.5 Scope
The work presented herein describes the cytokine signals sufficient for the
acquisition of a BMEM cell subset characterized by the expression of the
transcription factor T-box Expressed in T cells (T-BET, encoded by the gene
Tbx21).

In the first section, we describe how novel interactions between

canonical TFH cell cytokines in concert with innate signals drive T-BET
expression in the B lineage. Further, since T-BET+ BMEM cells are phenotypically
related to Age-associated B Cells (ABCs), we interrogated whether our model
predicts age-related dysregulation of immune function in the second section.
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2. IL-21 AND IL-4 RECIPROCALLY REGULATE T-BET IN B CELLS
2.1 INTRODUCTION
2.1.1 T-BET in immunity and B cells
The transcription factor T-BET is part of an ancient family of 18 T-box
transcription factors important for regulating many tissues and organs during
metazoan development (125). Although originally discovered in its role for TH1
lineage commitment and optimal IFNγ production (126-128), T-BET expression
arises in many immune cells and orchestrates cellular functions beyond specific
cytokine production (129, 130). Indeed, NK cell maturation and homeostasis,
and proper CD4 T cell chemotaxis all require T-BET expression (131, 132).
Thus, this transcription factor’s pleiotropic effects extend to a variety of immune
cells. B cell intrinsic T-BET expression fosters switching to IgG2a (111, 133-135),
an isotype associated with both TH1-driven antibody responses and humoral
autoimmunity (126, 136).

Moreover, T-BET is required for the generation of

ABCs, which are transcriptionally distinct from other B cell subsets and have also
been associated with both viral clearance and humoral autoimmunity (137-139).
A more detailed introduction on ABCs is provided in chapter 3.
Despite growing appreciation for the importance of T-BET-driven B cell
fates, the exact signals that yield B lineage effectors characterized by T-BET
expression – as well as how these regulate appropriate versus pathogenic
outcomes – remain poorly defined. Candidates include cell-intrinsic signals from
adaptive and innate receptors, including the BCR and TLRs, as well as signals
from TFH cells. In this regard, several TH1 cytokines, including IL-12, IL-18, and
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IFNγ, can induce T-BET in activated B cells (126, 136). Nonetheless, the roles
and interactions of canonical TFH cell cytokines – IL-21, IL-4, and IFNγ – in
regulating T-BET expression have not been systematically interrogated (101,
140, 141).
2.1.2 Cytokines regulate B cell responses
Generally, intercellular communication occurs via cell-to-cell contact or
secreted messengers. The latter includes a loosely categorized group of small
proteins called cytokines (~5-20kDa).

Importantly, these include interleukins,

chemokines, tumor necrosis factors, and interferons but generally not hormones
or growth factors (142). Thus, depending on type of cytokine produced, cytokinesecreting cells can regulate and instruct the behavior of other cells.

In this

regard, TFH cells guide and direct B cell responses via the production of IFNγ, IL4, and IL-21.

Beyond their capacity in driving affinity maturation, TFH cells

instruct isotype switching via these cytokines. Indeed, the effects of IFNγ and IL4 on antibody isotype determination have been long appreciated (140, 141, 143145). However, in addition to the effects of the hallmark cytokine of the TFH
lineage, IL-21 (146-149), how B cells integrate cytokine signals to achieve
appropriate isotype and fate decisions remains unclear (150, 151). Thus, careful
consideration of each cytokine is necessary to understand its attributed effects
on B cells.
While originally named for its capacity to promote antiviral activity in
influenza virus infected chick embryos (152, 153), IFNγ-producing cells regulate
a variety of cell-mediated immune responses. Indeed, natural killer (NK), CD8,
15

and TH1 cells all produce IFNγ against intracellular pathogens and tumors (154).
IFNγ functions by binding the IFNγR-α and -β chains, which drives JAK-induced
phosphorylation of STAT1 (pSTAT1).

The resulting pSTAT1 homodimer

translocates to the nucleus and initiates a change in gene expression (155). For
B cells, IFNγ drives CSR to the IgG2a/c and IgG3 isotypes (145, 156-158).
Moreover, IFNγ receptor deficient mice fail to induce a normal intracellular
pathogen IgG2a antibody response (159).

These observations lead to the

presumption that TFH cell-derived IFNγ drives antiviral antibody responses;
however, while global IFNγ is necessary for normal IgG2a responses, T cell
derived IFNγ seems redundant in this capacity (140). Thus, while IFNγ is
important for normal antibody responses against intracellular pathogens, the
cellular source acting directly on B cells remains unclear.
In contrast to how IFNγ was discovered, IL-4’s immunological role was
first shown by its direct action on B cells. IL-4 signals by binding the IL-4Rα and
IL-2 common-γ chain receptor, which drive JAK-mediated phosphorylation of
STAT6 (pSTAT6).

The resulting homodimer translocates to the nucleus and

drives transcription (160). Two research groups independently discovered IL-4
via its capacity to enhance B cell activation and drive CSR to IgG1 and IgE (161163). Further, in vivo evidence also confirms and extends IL-4’s role in inducing
these isotypes against extracellular pathogens (141, 143, 164); however, IL-4 is
not critical for host survival against these infections.
In addition to the well-characterized roles of IFNγ and IL-4 in isotype
determination, IL-21 also regulates B cell responses (165). IL-21 functions by
16

binding the IL-21R and IL-2 common-γ chain receptor, which drives JAKmediated phosphorylation of STAT1, 3, 5a, 5b (pSTAT1, 3, 5a, 5b).

The

resulting pSTAT homodimers and heterodimers (pSTAT1:pSTAT3) translocate to
the nucleus and initiate gene expression changes (166).

While originally

described for its role in NK cell expansion in vitro (167), subsequent serum
isotype analysis revealed a critical role for in regulating IgG1 production (168). In
this regard, IL-21 was thought to account for the residual IgG1 observed in IL-4 or
STAT6 deficient mice. Moreover, subsequent reports demonstrated how IL-21
induces the mutually antagonistic transcription factors BLIMP1 and BCL6, which
are critical for B cell fate determination (169). Indeed, given BCL6’s association
with the GC B cell fate, in vivo evidence also confirms IL-21’s direct role in GC B
cell maintenance presumably through BCL6 induction (150, 151). Thus, IL-21
regulates not only B cell fate decisions but also isotype determination.
2.1.3 CD11c expression in B cells
In addition to guiding cell fate decisions, cytokines also direct immune
cells to cites of inflammation via the induction of chemokine receptors and
integrins.

Indeed, IL-4, IFNγ, and IL-21 have all been shown to modulate

expression of trafficking proteins (170-173).

Integrins are a family of

heterodimeric cell adhesion receptors that mediate cellular migration, trafficking,
and cell-to-cell contacts via binding to cell-surface or extracellular matric ligands.
The heterodimers consist of α and β subunits. CD11a, CD11b, CD11c, and
CD11d are all α subunits that heterodimerize with the β2 subunit (CD18) (174,
175). Originally, CD11c was thought to demarcate DCs with high fidelity (176),
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and thus later developed into a DC-ablative tool (177); however, it is now
apparent that B and other cells normally express CD11c. Thus, it is important to
consider what this integrin does beyond its capacity to identify specific cell types.
Functionally, CD11c facilitates efficient phagocytosis and cell mobility via its
binding capacity of a variety of ligands including adhesion molecules (e.g. ICAMs
and VCAMs), LPS, complement protein, and matrix proteins such as fibrinogen
and collagen (175). In accord with these capacities attributed to CD11c, deficient
mice have compromised immune function. Indeed, CD11c deficient mice are
resistant to models of disease such as EAE and atherosclerosis and conversely
mount reduced responses to pathogen challenge (178-181). In the B lineage,
CD11c expression associates with viral or bacterial infections, autoimmunity, and
neoplasia (138, 182-187), although its function is unclear.

Thus, the signals

driving B cell intrinsic CD11c expression and the integrin’s role in normal or
aberrant immune responses are of interest.
2.1.4 Summary of findings
Here, we show that B cells integrate IL-4, IL-21, and IFNγ signals to adopt
distinct TBET+ effector fates. In the context of TLR engagement, both IL-21 and
IFNγ directly drive FO B cells to express T-BET in vitro.

However, IL-4

antagonizes IL-21-driven TBET upregulation, but enhances IFNγ-induced T-BET
expression.

Moreover, IL-21 but not IFNγ promotes CD11c expression.

Consistent with these in vitro results, the in vivo frequencies of GC B cells and
BMEM cells expressing T-BET or CD11c vary based on the prevailing cytokine
milieu. Finally, using viral and helminthic infections in single and double cytokine
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KO mice, we show that the relative abundance of these cytokines governs
whether GC and BMEM cells generated during ongoing immune responses
express T-BET and CD11c.

Together, these findings reveal a previously

unappreciated interplay between key TFH cytokines that, in concert with innate
sensors, controls the adoption of T-BET+ fates among antigen-experienced B
cells.
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2.2 MATERIALS AND METHODS
Mice
Tbx21-/-, Stat6-/-, Tbx21f/fCd19Cre/+, C57BL/6, and BALB/c mice were maintained
and used in accordance with the University of Pennsylvania Institutional Animal
Care and Use Committee (IACUC) guidelines.

University of Pennsylvania

IACUC approved all animal experiments. Il4-/- mice were a gift from Dr. Paula
Oliver.

Ifng-/- mice were a gift from Dr. Edward Behrens.

Il4-/-Ifng-/- double

deficient mice were bred in house. IL21r-/- and Il21Tg spleens and sera were
shipped overnight on ice from Dr. Warren Leonard’s mouse colony at the NIH.
All experimental mice were 2-6 months of age.
Infections
Mice

were

infected

by

oral

gavage

with

200

infectious

larvae

of

Heligmosomoides polygyrus (HP), which were generated as previously described
(188). Mice were infected by intranasal (i.n.) infection with 30 TCID50 of influenza
strain A/PR/8/34 (PR8) (ATCC).

Spleens and sera were harvested on days

indicated in figure legends.
In vitro cultures
CD23+ splenic B cells were enriched by positive selection using MACS bead
system (Miltenyi Biotec), labeled with either Violet Cell Trace (VCT, Invitrogen) or
carboxyfluorescein

succynimmidyl

ester

(CFSE,

eBioscience)

and

were

stimulated with 1uM ODN1826 (Invitrogen), 1ug/mL CLO97 (InvivoGen), F(ab)’2
fragments of 10 µg/mL anti-IgM (Jackson ImmunoResearch Laboratories), 10
µg/mL anti-CD40 (clone HM40-3; BL), 25 ng/mL IL21, 10 ng/mL IL4, 10 ng/mL
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IFNγ (Shenandoah Biotechnology) at 37°C and 5.5% CO2 in RPMI supplemented
with 10% characterized FBS (HyClone), 1% HEPES (Gibco), 1% glutamine
(Invitrogen), 50 µM 2-mercaptoethanol (Gibco), 1% minimal essential amino
acids (Gibco), and 1% OPI supplement (Sigma).
Flow Cytometry
Spleens were harvested at indicated days post immunization or infection,
mashed between frosted glass slides, and filtered through 0.2 micron mesh.
Antibodies or reagents reactive to the following antigens were purchased from
BioLegend (BL), Beckton-Dickenson (BD), or eBioscience (eBio): T-BET (4B10,
BL), CD11c (N418, BL), IgM (R6-60.2, BD), CD38 (90, eBio), CD138 (281-2, BL),
IgD (11–26c.2a, BL), CD4 (RM4-5, BL), B220 (RA3-6B2, BL), CD62L (MEL-14,
eBio), TCR-β (H57-597, BL), CD19 (6D5, BL), CXCR5 (L138D7, BL); PD-1
(RMP1-30, BL); and PNA-FITC (Sigma), CD8 (53-6.7, eBio), CD4 (H129.19, BL),
F4/80 (BM8, eBio), Ly-6G/GR1 (RB6-8C5, eBio). Exclusion based on Zombie
Aqua (BL) positivity was used to identify live cells, and doublets were excluded
by forward and side scatter height versus width analyses. Cells were analyzed on
an LSRII or sorted on an Aria II (BD), and data analyzed using FlowJo software
(Tree Star). Intracellular stains were performed using the eBioscience Foxp3
transcription factor kit.
Serum antibody titers and PR8-specific ELISA
For ELISA, Immunosorb plates (Corning) were coated with 20 hemagglutination
units (HAU) PR8 or 10 µg/ml anti-mouse heavy and light chain, and blocked with
PBS containing 2% BSA. Virus used for coating ELISA plates was inactivated by
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incubation with 0.1% beta-propiolactone (BPL; Sigma) and 0.1 M HEPES
(Cellgro) overnight at 4C followed by a 90 minute incubation at 37C. Diluted sera
were incubated for 1 hour at room temperature, detected with horseradish
peroxidase conjugated goat anti–mouse IgG2a, IgG2b, IgG2c, or IgG1 antibodies
(SouthernBiotech), and developed with using 3,3’, 5,5’ tetramethylbenzidine
(TMB) substrate (BD). Color development was terminated with 2M H2SO4 then
read on an EMax microplate reader (Molecular Devices) at 450nm.
Quantitative PCR analysis
RNA was extracted with the RNeasy kit (QIAGEN) and reverse transcribed using
SuperScript II Reverse transcription (Invitrogen) according to the manufacturer’s
protocols. cDNA was amplified using TaqMan Universal Master Mix (Applied
Biosystems) and Taqman probes for various genes (Applied Biosystems). Realtime PCR was performed with an ABI 7300 (Applied Biosystems). Relative
expression (ΔΔCt) was calculated using Gapdh (Mm99999915_g1) expression as
an endogenous control for cells that were FACS sorted ex vivo or stimulated in
vitro.

Probes:

Il4

(Mm00445260_m1),

Ifng

(Mm00801778_m1),

Il21

(Mm00517640_m1), Tbx21 (Mm00450960_m1), Aicda (Mm00507774_m1).
Transcriptional profiling and functional enrichment analysis
After 20 hours in vitro stimulation as described above, RNA was isolated using
the miRNeasy kit (Qiagen). Biotin-labeled complementary RNA (cRNA) was
generated using the Illumina TotalPrep RNA amplification kit (Ambion). Illumina
MouseRef-8 v2.0 expression Beadarrays were hybridized with cRNA. Scanned
images were converted to raw expression using GenomeStudio v1.8 software
22

(Illumina). Data analysis was carried out using the statistical computing
environment, R (v3.0.2). Differentially expressed genes (1.5-fold, FDR ≤ 0.05)
were identified by linear modeling and Bayesian statistics using the Limma
package (189). Clusters of co-regulated genes were identified by Pearson
correlation using the hclust function of the stats package in R. Data have been
deposited on the Gene Expression Omnibus (GEO) database for public access
(Accession # GSE77145).
Statistics
Student’s t-test was used to generate all P-values, * P <0.05, ** P <0.01, *** P
<0.001, **** P <0.0001. All error bars are S.E.M. based on biological replicates.
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2.3 RESULTS
2.3.1 IL-21, IL-4, and IFNγ differentially regulate T-BET and CD11c
expression
In preliminary in vitro studies, we established that IL-21 drives TBET
expression in FO B cells responding to TLR9, but neither BCR (α-IgM) nor CD40
signals (Figure 1A). To explore these interactions further, we cultured FO B
cells with IL-4, IL-21, or IFNγ in the presence of TLR7 or TLR9 agonists. Both
Tbx21 transcripts and TBET protein increased markedly in FO B cells cultured
with IL-21 or IFNγ (Figures 1B and C), but IL-4 influenced these outcomes
differently. IL-4 blocked IL-21-driven TBET upregulation, but enhanced IFNγmediated TBET upregulation (Figures 1B and C). Furthermore, IL-4 mediated
these effects in a dose dependent manner when applied concomitantly with
ODN1826 and IL-21 (Figure 1D).
To determine whether IL-21 and IL-4 directly regulate TBET in B cells,
either Il21r-/- or Stat6-/- B cells were co-cultured with wild type (WT) B cells and
stimulated as above. Since STAT6 is the key signal transducer of IL-4 and IL21R is required for IL-21 signaling (167, 190), we reasoned that co-culturing
these mutants with WT cells would reveal any secondary trans effects of cytokine
treatment.

In order to track cell type and expansion, WT or KO cells were

labeled with VCT or CFSE, respectively (Figure 2A, top row). While IL-21induced TBET expression in WT B cells, the co-cultured Il21r-/- B cells remained
TBET negative, despite dividing to a similar extent. Analogously, although IL-21driven TBET upregulation in WT B cells was reversed by IL-4, co-cultured Stat6-/24
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Figure 1. IL-4 and IL-21 reciprocally regulate T-BET expression in vitro. All in
vitro experiments used magnetically enriched CD23+ splenocytes (FO B cells). (A)
WT or Cd19cre/+Tbx21f/f B cells were cultured with indicated stimuli for 48hrs and
probed for T-BET (ΔMFI=WT-mutant). (B) Tbx21 Gene expression analysis (ΔΔCt)
from WT B cells treated for 20hrs with indicated stimuli. (C) FO B cells treated as
in (B) for 48h and probed for T-BET. ** P <0.01, *** P <0.001, n = 3 independent
experiments. (D) WT FO B cells cultured with ODN1826 and IL-21 with IL-4 titration and probed for TBET. (B-C) Data are presented as means of biological replicates ± SEM.
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Figure 2. IL-4 and IL-21 act in a cell intrinsic manner to regulate T-BET
expression in vitro. All in vitro experiments used magnetically enriched CD23+
splenocytes (FO B cells). (A and B) FO B cells from WT, Il21r-/-, or Stat6-/- spleens
were labeled with either CFSE or Violet Cell Trace (VCT), treated with ODN1826
and indicated cytokine combinations for 48h, and assessed for CD11c and T-BET.
n = 3 independent experiments.
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cells were refractory to this negative regulatory effect (Figure 2A, bottom row).
These results show that B cell intrinsic IL-21 and IL-4 signals directly and
reciprocally regulate TBET expression in the context of TLR9 driven activation.
Importantly, IFNγ treatment induced TBET irrespective of Il21r or Stat6 deficiency
(Figure 2B).

The converse effects of IL-4 on IFNγ- vs IL-21-induced TBET

expression suggests that unique, TBET-associated fates are likely facilitated by
each cytokine. We further interrogated this possibility in several ways. First,
since previous studies have linked TBET with CD11c expression (138), we asked
whether IFNγ or IL-21 influence CD11c differently.

The results show that

whereas IL-21 drives CD11c expression, IFNγ does not (Figure 2). Further,
similar to its effects on TBET, IL-4 blocks IL-21-induced CD11c expression.
These findings indicate that IL-21 and IFNγ drive TBET expression through
distinct mediators. Further, TBET expression is not sufficient for the induction of
CD11c. Thus, TBET and CD11c are each directly but separately regulated by IL21 and IFNγ.
To further interrogate the distinct TBET+ B cell fates driven by IL-21 versus
IFNγ, as well as to distinguish TBET-dependent and -independent effects of each
cytokine, we performed genome-wide transcriptional profiling on WT or Tbx21-/- B
cells stimulated with either IFNγ or IL-21. Principal components analysis shows
that 82.7% of variance in these data was explained by the cytokine employed,
while Tbx21 genotype accounted for 6.3% of the variance (Figure 3A). Further,
each cytokine induces a unique transcriptional profile, including some T-BETdependent shifts in gene expression (Figure 3B and Table I). We confirmed that
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Figure 3. IL-21 drives T-BET-dependent shifts in gene expression distinct
from IFNγ. All in vitro experiments used magnetically enriched CD23+ splenocytes (FO B cells). WT or Tbx21-/- FO B cells were cultured for 20h with IL-21 (21)
or IFNγ (γ) with ODN1826, RNA was harvested, and principal component (A) and
Z-score (B) analysis performed according to materials and methods.
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9.49
8.62
10.82
10.02
10.49
10.45
11.46
12.07
9.92
10.52
9.64
10.37
11.29
11.39
10.43
10.31
11.50
9.57
12.33

Tbx21 KO
IL21
IFNG
9.96
8.72
11.88
9.63
9.79
10.17
9.56
8.38
9.57
8.16
8.17
8.08
10.89
12.33
8.47
8.34
11.48
10.21
10.26
11.03
7.96
8.02
8.29
9.05
11.02
11.22
8.79
8.56
9.19
8.80
10.42
10.28
8.90
9.03
9.32
10.30
9.66
9.18
11.08
10.61
11.87
10.90
8.05
9.70
8.07
8.44
9.03
9.44
10.33
11.35
9.34
9.22
8.31
8.39
10.99
10.68
10.74
10.94
9.08
10.03
11.82
11.13
8.36
8.71
9.85
9.44
9.69
11.67
8.60
10.64
10.92
11.14
11.34
11.07
10.70
10.77
8.29
8.51
8.93
9.26
10.39
11.68
9.24
10.42
9.88
9.74
11.96
11.96
11.82
12.07
10.07
9.67
11.42
10.96
12.40
10.68
8.67
8.97
13.72
12.93

Table II: Top 50 differentially expressed genes.
Top 50 genes differentially expressed according to stimulation and genotype
generating the heatmap in Figure 3B.
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Tbx21 expression was high in WT mice and low in KOs thus validating our
dataset. We find that IFNγ strongly and uniquely induced some genes, including
Cxcl10 and Socs2, which were highly T-BET dependent. Moreover, IL-21 also
induced its own unique set of T-BET dependent genes including Aicda and Cd86.
Additionally, there are some T-BET sensitive genes, such as Cxcr3, that were
induced by both cytokines.

Lastly, in accord with T-BET’s role as a

transcriptional repressor (191, 192), we also found some genes that were
potently induced in the absence of T-BET such as Trib3, Csprs, and Slc7a3.
Thus, although IFNγ and IL-21 overlap in regulating some T-BET dependent
genes, each drives a unique transcriptional profile.
2.3.2 Relative abundance of IL-21, IL-4, and IFNγ regulate T-BET
expression in vivo
Our in vitro findings suggest that IFNγ, IL4, and IL21 interact to modulate
TBET and CD11c expression in B cells. As an initial assessment of whether this
relationship exists in vivo, we surveyed GC B and BMEM cells for TBET
expression in C57BL/6 (B6) versus BALB/c mice (Figure 4A), because these
strains display inherent TH1 versus TH2 skewing, respectively (193).

We

reasoned that if TBET expression is promoted by milieus rich in IFNγ, but
repressed in those with plentiful IL-4 and little IFNγ, then the frequencies of
TBET+ B cells in these two strains should differ. In agreement with this prediction,
most GC B cells in B6 mice are TBET+ (Figure 4B), and variable CD11c
expression was restricted to BMEM cells (Figure 4C). In contrast, BALB/c mice
lack TBET+ B cells (Figure 4B), despite a small cohort of TBET-CD11c+ BMEM
30

A

Live singlets,
IgD-, Gr-1-,
F4/80-, CD4-, CD825.9
0.96
PC

Non-PCs, B220+
6.62

Switched B cells
19.5
GC B

CD138

B

PNA

IgM

B220

BMEM

CD19

GC B cells,
(PNA+CD38-)

BMEM (PNA-CD38+)
1.06

CD11c

% of Max

CD38

C

B6
BALB/c
iso

T-BET

68.8

7.52

BALB/c

B6

T-BET

Figure 4. Genetic background determines T-BET expression in vivo. (A) Representative FACS gating strategy for activated splenic B cell subsets including
PCs, GC B, and BMEM cells. (B) Representative intracellular T-BET staining on
C57BL/6 (B6) or BALB/c GC B cells and (C) T-BET and CD11c on BMEM cells. n =
3 experiments.
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cells (Figure 4C). These findings are consistent with the notion that IFNγ and IL4 levels regulate TBET expression in GC B cells. To probe the impact of IL-21
on this overall relationship, we next asked whether extra-physiological levels of
IL-21 would foster accumulation of TBET+CD11c+ B cells. Although the partially
activated state of B cells in these mice confounds conventional phenotyping
strategies (Figure 5A), nearly all mature B cells in Il21-Tg bear a CD23-CD21phenotype

identical

to

the

TBET-dependent

ABC

subset

(169,

194).

Furthermore, surface IgD and IgM expression on B-2 B cells reveals that excess
IL21 does not drive profound switching to other isotypes (Figure 5A, far right).
Regardless, profound increases in both TBET and CD11c expression were seen
in all splenic B-2 B cells in Il21-Tg mice (Figure 5B), which is consistent with our
in vitro results suggesting that IL-21 drives both TBET and CD11c expression.
Furthermore,

analysis

of

antigen-experience

subsets

indicates

that

TBET+CD11c+ accumulate in many different activated B cell subsets (Figures
6A&B).

Finally, consistent with TBET’s role in fostering class switch

recombination to IgG2a/c, we observed a marked increase of IgG2a/c but not IgG1
serum antibody titers in Il21-Tg compared to WT mice (Figure 5C).
Together, our in vitro and in vivo observations prompt a model in which
the relative availability of IL-4, IL-21, and IFNγ govern the likelihood of
establishing BMEM cells expressing TBET and CD11c. Further, they suggest that
abundant IFNγ will drive a TBET+CD11c- B cell fate regardless of IL-4 or IL-21
levels, but that in the absence of IFNγ, the TBET+CD11c+ fate will be reciprocally
regulated by IL-21 versus IL-4. We therefore evaluated these predictions by
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Figure 5. IL-21 overexpression in vivo generates T-BET+CD11c+ pre-immune
B cells. (A) Representative FACS gating strategy for activated splenic B cells from
WT and Il21Tg mice including FO, MZ, and “ABCs”. (B) Representative FACS
staining for T-BET and CD11c on splenic B-2 B cells . n = 3 independent experiments with 3 mice per group. (C) Total serum IgG1 or IgG2a/c (IgG2a + IgG2c) titers
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mice per group. Data are presented as means of biological replicates ± SEM.
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tracking the immune responses to either influenza virus or H. polygyrus infections
in mice where cytokine availability could be experimentally manipulated.
2.3.3 Influenza virus infection generates T-BET+CD11c+ BMEM in the absence
of IL-4 and IFNγ
Influenza virus infection results in a well-characterized T-dependent and
TH1-skewed response, in which responding TFH cells produce copious IFNγ as
well as IL-21 and IL-4 (140). Thus, we reasoned that IFNγ would induce T-BET
expression in GC B and BMEM cells, but in the absence of IFNγ, IL-4 would
prevent TBET expression. Accordingly, WT or Ifng-/- mice were infected with the
A/Puerto Rico/8/1934 H1N1 influenza virus strain (PR8).

As expected, WT

animals mounted a robust GC B cell response to PR8 (Figure 7A), and these
GC B cells expressed T-BET (Figure 7B). In contrast, GC B cells in Ifng-/- mice
failed to express T-BET (Figure 7B) even though the magnitude of the GC B cell
response was similar to WT (Figures 7A&C). Although the splenic PC numbers
were reduced in Ifng-/- mice, BMEM cell numbers remained intact across
genotypes (Figures 7D & 7E). Thus, although the magnitude of the response
varied slightly across gentoypes, all infected mice mounted a response above
non-infected controls.
To confirm the intracellular T-BET staining and assess the cytokine profile
of TFH cells, we sorted both GC B cells and TFH cells from each genotype (Figure
8A). Indeed, gene expression of Tbx21 from FACS sorted GC B cells in WT and
Ifng-/- mice confirmed our intracellular T-BET stain (Figure 8B).

Next, we

confirmed that FACS sorted TFH cells from WT and Ifng-/- mice expressed equal
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Figure 7. Influenza virus infection drives T-BET+ GC B cells formation in the
absence of IFNγ and IL-4. All figures based on FACS stained splenocytes from
non-infected or day 10 post i.n. 30 TCID50 PR8 infection in WT (n=21), Ifng-/(n=13), and Il4-/-Ifng-/- (n=13) mice across 3-7 experiments with ≥3 mice per group,
** P <0.01. (A) Representative FACS gating strategy for PCs, GC B, and BMEM
cells. (B) Representative FACS staining for T-BET on GC B cells. Enumeration of
(C) GC B cells (D) PCs, and (E) BMEM cells.
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levels of Il4 and Il21 transcripts (Figures 8C & D). Moreover, although reduced
in magnitude, Ifng-/- mice mounted a comparable TFH cell response to WT
controls (Figure 8E).

These results are consistent with the idea that in the

absence of IFNγ, IL-4 blocks T-BET expression in response to IL-21. To directly
test this, we infected Il4-/-Ifng-/- double deficient mice with PR8. While Il4-/-Ifng-/mice mounted a blunted GC B cell response (Figures 7A&C), these cells
nonetheless clearly expressed T-BET (Figures 7B & 8B). Furthermore, only the
GC B cell response was blunted in Il4-/-Ifng-/- mice (Figure 7C), whereas the PC
and BMEM were comparable to WT (Figures 7D&E).

Lastly, Il4-/-Ifng-/- mice

mounted a comparable TFH cell response with the same levels of Il21 transcripts
as WT (Figures 8D&E).
We next assessed BMEM cells for T-BET and CD11c expression and
probed the serum for IgG2c or IgG1 PR8-reactive antibody given our initial
phenotypic studies (Figures 4C & 5C). The composition of the BMEM cell pool
differed according to genotype in response to infection (Figures 9A&B). While
WT mice generated some T-BET+CD11c+ BMEM cells, Ifng-/- mice produced
almost none above non-infected controls, suggesting the dominance of IL-4 in
the absence of IFNγ. Lastly, Il4-/-Ifng-/- mice produced the most TBET+CD11c+
BMEM cells, presumably reflecting IL-21 activity in the absence of any repressive
IL-4 effects. Furthermore, we assessed PR8 reactive serum antibody titers of the
IgG2c and IgG1 isotypes and asked whether they correlated with T-BET
expression. Consistent with the role of IgG2c in antiviral immunity (195, 196), WT
mice produced the most PR8-reactive IgG2c compared to Ifng-/- and Il4-/-Ifng-/37
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mice (Figure 9C). Importantly, a substantial amount of antigen specific IgG2c is
independent of both IFNγ and B cell intrinsic T-BET expression. Lastly, PR8reactive IgG1 was most prominent in Ifng-/- mice, which is consistent with an IL-4
dominant response.

Overall, these findings confirm and extend our in vitro

findings, since the same interplay of cytokines directs T-BET expression among
B effectors in vivo. Further, our observations suggest that T-BET+CD11c+ BMEM
cells will be fostered in immune responses where IL-4 and IFNγ are limited.
2.3.4

Il-4

deficiency

is

sufficient

to

induce

T-BET+CD11c+

BMEM

independently of IFNγ in Heligmosomoides polygyrus infection
Results with influenza virus infection are consistent with the notion that
IFNγ drives T-BET expression irrespective of concomitant IL-4 or IL-21, and that
eliminating IFNγ creates a situation where the relative levels of IL-4 and IL-21
govern the T-BET+CD11c+ phenotype. However, this subtractive approach does
not necessarily show that in responses where IFNγ is normally absent, the sole
determinant of a T-BET+ fate is IL-4 availability. Accordingly, we asked whether
IL- deficiency is sufficient to permit T-BET expression in GC B cells during a TH2
response, using Heligmosomoides polygyrus (HP).

This intestinal helminth

induces IL-4 and IL-21 production by TFH cells, which drives a robust IgG1
response (141). Thus, we hypothesized that in the absence of IL-4, IL-21 would
be sufficient to induce T-BET expression in B effectors. To test this idea, we
infected WT or Il4-/- mice with HP, and probed GC B cells for T-BET.

As

expected, WT mice mounted a GC B cell response that lacked T-BET expression
(Figures 10A-C). Conversely, although blunted in magnitude, Il4-/- mice initiated
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cells formation in the absence of IFNγ and IL-4. All figures based on FACS
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a TBET+ GC B cell response. To eliminate the possibility that excess IFNγ in Il4-/mice explains these phenotypes, we infected Il4-/-Ifng-/- mice with HP. The GC B
cell response in Il4-/-Ifng-/- mice was restored to WT levels (Figure 10C) but
maintained T-BET expression independently of IFNγ (Figure 10B). Importantly,
the magnitude of the PC and BMEM cell response remained intact across
genotypes (Figures 10D&E).
To confirm the intracellular T-BET staining and assess TFH cell cytokine
profile, we sorted both GC B and TFH cells from each genotype (Figure 11A).
Tbx21 gene expression from FACS sorted GC B cells in WT, Ifng-/-, and Il4-/-Ifng-/mice confirmed the intracellular T-BET stain (Figure 11B). Further, TFH cells
from both Il4-/- and Il4-/-Ifng-/- mice produced less Il21 even though these mice
generated comparable or more TFH cells than WT (Figures 11C&D). Finally, we
again assessed BMEM cells for TBET and CD11c expression and probed the
serum for serum IgG2c or IgG1. We observed a similar alteration in the BMEM pool
according to cytokine availability. Whereas HP-infected WT mice did not
generate T-BET+CD11c+ BMEM cells, both Il4-/- and Il4-/-Ifng-/- mice did—again
suggesting an IL-21-driven phenotype independent of IFNγ (Figures 12A&B).
Isotype representation varied with T-BET expression: whereas WT mice
produced >95% IgG1, over half of the serum antibodies in Il4-/-Ifng-/- and Il4-/- mice
were IgG2b and IgG2c (Figure 10C). Overall, the HP infection data are consistent
with our model inasmuch as in the absence of IFNγ production, we observe TBET and CD11c expression that is sensitive to IL-4. Moreover, the consistent
relationship of these cytokines to T-BET and CD11c expression in both types of
42

infection suggest a common feature to most humoral immune responses.
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2.4 DISCUSSION
Together, these results show that in the context of TLR7 or TLR9
engagement, the aggregate of IFNγ, IL-21, and IL-4 signals determines whether
B cells adopt a T-BET+ fate. We provide in vitro evidence for a novel route to TBET induction via the hallmark TFH cell cytokine, IL-21. Importantly, this occurs
robustly in the context of TLR engagement and independent of antigen receptor
engagement or costimulation. Furthermore, concomitant IL-4 signals antagonize
IL-21-induced T-BET expression but enhance IFNγ-driven T-BET. Moreover, IL21, but not IFNγ, promotes CD11c expression independent of T-BET. Using
influenza virus and H. polygyrus infections, we show that these interactions
function in vivo to determine whether T-BET+ and CD11c+ B cells are formed.
These findings suggest that T-BET+ B cells seen in health and disease share the
common initiating features of TLR driven activation within this circumscribed
cytokine milieu.
TLR engagement appears necessary to position activated B cells for these
fates upon subsequent IL-21 signaling. We have obtained similar results with the
TLR2/4 ligand LPS (Figure 13A), suggesting pathways common to most TLRs,
and perhaps other innate receptors, provide these key initial signals.

We

speculate that these innate signals alter gene loci accessibility for subsequent
TFH cytokine cues since there are reports of crosstalk between the TLR-MyD88
and IL-21r-STAT3 pathways in B cells (197, 198). Indeed, prior reports that
CD11c+ or TBET+ B cells emerge in responses to a variety of viral and bacterial
infections are consistent with this idea (137, 183). Furthermore, while BCR and
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Figure 13. Dominant IFNγ-driven T-BET expression. All in vitro experiments
used magnetically enriched CD23+ splenocytes (FO B cells). FO B cells treated
with LPS (A) or ODN1826 (B&C) and indicated cytokine combinations for 48h, and
assessed for T-BET and CD11c. n = 3 independent experiments.
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CD40 engagement do not induce T-BET with IL-21, these signals do consistently
down-modulate the levels of T-BET expression induced by ODN1826 and IL-21
(Figure 1A). This further suggests complexity among the NF-κB, STAT, and
MyD88 signal cascades.

Thus, understanding how B cells integrate these

disparate signal transduction events should elucidate effector cell fate decisions.
The differential effects of IL4 on IL21 versus IFNγ suggest a complex
interplay of STAT-dependent transcriptional regulation. The clear dose-response
relationship of IL4-mediated effects is consistent with the idea that competitive
relationships are involved (Figure 1D).

Furthermore, IL-21-driven T-BET

remains sensitive to IL-4 signals even 20 hours after it is induced (Figure 13B).
This suggests that IL-21-induced T-BET fates are plastic in vitro and still subject
to the repressive activity of IL-4.

Although IL-4Rα and IL-21R both require

common-γ chain receptor to phosphorylate their associated STATs (199), our
Stat6-/- coculture data indicate that competition for membrane proximal receptor
components is unlikely to explain these findings (Figure 2). If this were the case,
then Stat6-/- cells would also be subject to IL4’s repressive effects.

Instead,

downstream events are more likely candidates, including differential occupation
of transcriptional regulatory sites, and altered stoichiometric relationships among
the JAK-STAT proteins involved. In T cells, it is established that IL-21 can drive
T-BET in a STAT1 dependent manner (200, 201); however, IL-21 transduced
signals have not been so carefully characterized in the B lineage.

Thus,

assessing whether IL-21-driven pSTAT1 or pSTAT3 is altered by IL-4 or whether
STAT6 binds the Tbx21 locus could elucidate the mechanism behind the
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interplay of IL-21 and IL-4 on T-BET expression.
The preferential induction of CD11c and differential effects of IL-4
stimulation lead us to the conclusion that IL-21 and IFNγ drive distinct T-BET+
fates. Thus, since T-BET is a transcription factor, we explored how these two TBET inducing stimuli differed in terms of gene expression in the presence or
absence of T-BET (Figure 3).

The most striking difference was between

cytokine treatments as measured by principal component analysis (Figure 3A).
However, each cytokine treatment induces and represses overlapping and
distinct sets of genes in a T-BET dependent manner (Figure 3B). Specifically, in
accord with its role in GC maintenance, IL-21 induced Aicda and Cd86, which are
both critical for SHM and CSR (93, 202). Consistent with prior reports showing
IL-21 driven Aicda and Cd86 expression, and we further show that IL-21 induced
Aicda and Cd86 expression depends on T-BET (203, 204). Overall, IL-21 drives
a gene expression profile most consistent with that of the GC B cell fate.
Although overlap exists, the T-BET-dependent induction of Cxcl10 by IFNγ and
not IL-21 further confirms the notion that these two stimuli are distinct. Lastly,
each cytokine represses a set of genes in a T-BET dependent manner. Although
currently most of these genes have poorly defined immunological roles, Trib3 has
been shown to directly bind and disrupt to Akt kinase activity suggesting it may
have a role in nutrient sensing. Overall, these transcriptional analyses further
confirm that IFNγ and IL-21 drive distinct T-BET+ fates.
Our findings reveal a TFH cytokine network that governs T-BET+ B cell fate
decisions in the context of TLR stimulation. In accord with pervious reports, IFNγ
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drives T-BET expression and is not appreciably influenced by the presence of
either IL-4 or IL-21 (Figure 13C). Conversely, in the absence of IFNγ, IL-4 and
IL-21 reciprocally regulate T-BET and CD11c expression both in vitro and in vivo.
Since immune responses are rarely monolithic with regard to these three
cytokines (140, 205), we suggest that the resulting multifunctional TFH cells can
generate a diverse set of B effectors. Consequently, altering the cytokine milieu
affects the isotypes generated (Figures 9C&D and 12C) and the composition of
the BMEM pools (Figure 9A&B and 12A&B) while largely maintaining the
magnitude of the response.

Since T-BET+CD11c+ B cells are observed in

autoimmunity, viral infections, and aging, it is tempting to speculate that an
underlying common feature is endosomal TLR engagement coupled with either
copious IFNγ or abundant IL-21 with little IL-4. Indeed, both TLR7 and IL-21
deficiencies ameliorate disease in humoral autoimmunity models (206-209), and
poor IL-4 production has been observed in TFH from aged mice (210). Thus,
understanding this interplay among IL-4, IL-21, and IFNγ might better define the
etiology of humoral autoimmunity where ABC-like cells are observed (138, 187,
211, 212).
While it is clear that IFNγ and IL-21 differentially induce CD11c expression
(Figure 2), the functional consequences of expressing this integrin remain
elusive.

Importantly, the restriction of CD11c expression to BMEM cells is

consistent with prior BMEM subsetting studies in human tonsils and may thus
define a tissue-homing population (185). While CD11c expression per se does
not define tissue residency, future studies should assess whether altered integrin
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and chemokine expression occurs on BMEM cells generated in skewed cytokine
milieus. Indeed, TFH cells have been reported to produce every individual and
combinatorial permutation of IL-4, IL-21, and IFNγ (140, 205). Thus, since a
normal humoral immune response generates various pools of cytokine-skewed
TFH cells, they consequently drive a diverse array of B cell effectors.

This

assortment of effectors may be beneficial to host protection because adopting a
singular strategy of immunity may be deleterious for the organism.
Finally, the most prominent B cell role, Ig production, is significantly
affected in our infection models. In accord with previous reports, we observe that
B cell intrinsic TBET expression during PR8 infection correlates with IgG2c
production in WT mice (111). However, even though Ifng-/- mice did not express
TBET in B cells (Figures 7B and 8B), they produced as much PR8-reactive
IgG2c antibody as Il4-/-Ifng-/- (Figure 9C) where prominent T-BET expression was
observed.

Thus, a substantial amount of IgG2c is both IFNγ and T-BET

independent. These observations are consistent with a prior report showing that
TI-generated IgG2c is T-BET-dependent whereas IgG2c from TD responses is not
(133). If the remaining IgG2c PR8-reactive antibodies detected in Ifng-/- or Il4-/Ifng-/- mice are solely a result of a TD response, then the BMEM clones and PR8
anti-sera in these mice should be of higher affinity than their WT counterparts.
Although the HP infection experiments match current dogma regarding TBET
expression and IgG2c production (Figure 12C), these data also suggest that IL21 can drive IgG2c production independently of IFNγ. Again, how IFNγ and IL-21
drive different but related cell fates remains unclear but could reflect an
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extrafollicular versus GC response. Overall, these studies expose a thus far
poorly understood pathway to IgG2c switching involving IL-21 and some
transcriptional switch factor.

Given role of IgG2c autoinflammatory diseases

(213), exploring how this pathway leads to IgG2c production could underscore the
etiology of some humoral autoimmune diseases.
Together, our in vitro and in vivo observations prompt a model in which
the relative availability of IL-4, IL-21, and IFNγ govern the likelihood of
establishing BMEM cells expressing T-BET and CD11c. Further, they suggest that
abundant IFNγ will drive a T-BET+CD11c- B cell fate regardless of IL-4 or IL-21
levels, but that in the absence of IFNγ, the T-BET+CD11c+ fate will be
reciprocally regulated by IL-21 versus IL-4 (Figure 14). Further, although both
IFNγ and IL-21 induce TBET expression, IFNγ blunts IL-21-driven CD11c
expression (Figure 13C). This reinforces the notion that IFNγ-induced TBET is
refractory to the concomitant IL-4 or IL-21 signals, and therefore it is the
dominant of the three cytokines for TBET induction.
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T-BET+CD11c+

IL-21
IL-4

T-BET+

IFNγ

Figure 14. Model of IL-4, IL-21, and IFNγ interplay on T-BET expression.
IL-21 uniquely induces both T-BET and CD11c expression. IL-4 blocks the capacity
of IL-21 to drive TBET and CD11c expression but enhances the ability of IFNγ to
induce T-BET. IFNγ either actively blocks IL-21-induced CD11c expression or
dominantly drives T-BET expression alone.
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3. ABCs IN PROTECTIVE AND AUTOREACTIVE RESPONSES
3.1 INTRODUCTION
3.1.1 Dysregulation of the immune system associates with age
Advancing age is accompanied by far-reaching shifts in immune system
development and function, including reduced lymphopoiesis (214-217), blunted
primary

and

recall

immune

responses

(218-233),

the

appearance

of

autoantibodies (234-239), and increased frequencies of autoimmune and
autoinflammatory conditions (240). Accordingly, shifts in the generation and
relative representation of lymphocyte subsets have been scrutinized as potential
mechanisms underlying these features. Within the T lymphocyte lineage, thymic
involution, reduced T lineage specification, and an inversion in the ratio of naïve
to memory T lymphocytes are established age-associated phenomena (215, 228,
236, 241-247), and more recent studies have linked these shifts to compromised
vaccine and disease responses. Within the B lineage, similar reductions in early
lineage specification and shifts in the sizes and kinetics of developing B cell
pools have also been appreciated for some time (214, 216, 217, 222, 224, 226,
248-253). However, despite numerous clues indicating changes in the functional
attributes of peripheral B cells with age (222, 223, 235, 252, 254-257), whether
shifts in pre-immune and antigen experienced B cell subsets occur with age, as
well as the functional consequences of such changes, remained unclear until
recently. Within this context, a B cell subset with unique functional properties was
identified and characterized.
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3.1.2 ABCs emerge with age and have a unique surface marker phenotype
ABCs were first described in simultaneous reports from Hao et al and
Rubstov et al, using distinct but largely complimentary phenotypic and functional
criteria (194, 258) (reviewed in (259)). As their name implies, the ABC pool
emerges in mid-life and continuously enlarges with advancing age. Thus, in
healthy adult mice, ABCs are either absent or comprise a negligible proportion of
peripheral B cells until about 12 months of age, then increase steadily in both
proportion and number (194, 258-260). ABCs are observed in multiple inbred
strains and F1 combinations, suggesting they are a common feature of the aging
B cell pool (194).

Although the tempo with which ABCs emerge varies

considerably among individuals, they generally comprise 30-40% of mature
recirculating B cells by 24-30 months of age (260). Moreover, ABCs tend to
appear sooner and achieve higher numbers and representation in females (258),
although the exact basis for this sex-associated dichotomy is unclear [discussed
in (259)].
ABCs display a distinct surface phenotype in mice (Table I). They are
mature B cells, as evidenced by their lack of CD93. Further, while positive for
both B220 and CD19, they lack the canonical FO, MZ or B1 B cell markers
CD23, CD21 and CD43, respectively.

Detailed phenotypic, functional, and

transcriptional analyses confirmed that ABCs differ from all previously defined B
cell subsets.

Whereas Hao et al (194) used this combination of features to

define the population, Rubtsov et al (258) employed CD11c as a singularly
characteristic marker. Thus, while the B cell population circumscribed by the
55

criteria in Hao et al includes the CD11c+ cells of Rubtsov et al, it also captures
additional cells that lack CD11c. This distinction may underlie some apparent
differences in functional attributes.
Anatomically, ABCs are found in the blood, spleen, and BM, but are rarely
observed in lymph nodes (194). While these qualities suggest they are circulating
cells, multiple observations suggest their trafficking and homing patters differ
from FO B cells and other recirculating subsets. For example, expression of the
follicle homing factor CXCR5 is reduced on ABCs (194), and more recent studies
reveal they are enriched at the splenic T:B border, presumably reflecting
migratory differences imparted by increased CCR7 expression (261). Based on
these observations, it is tempting to speculate that ABCs may be involved in the
age-associated alterations in MZ composition previously reported by Birjandi et al
(262). Further, based upon their absence from the lymphatics, coupled with the
lack of formal studies probing their circulatory properties, it remains possible that
some ABCs are sessile tissue resident cells. In this regard, further phenotypic
analysis of ABCs may reveal their origins and function in health and disease.
3.1.3 ABC activation and survival requirements differ from those of other B
cell subsets
In addition to their distinct phenotype and localization characteristics,
ABCs display unique activation requisites and functional attributes. Initial in vitro
studies revealed that, unlike TR, FO, or MZ B cells, ABCs fail to proliferate after
BCR cross-linking, but nonetheless survive (194). In contrast, they exhibit robust
proliferative responses to stimulation via TLR9 or TLR7, and despite being
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refractory to BCR cross-linking alone, concomitant BCR engagement potentiates
their proliferative responses to TLR ligands (194, 258). Consistent with these
observations, both TLR9 and TLR7 expression are elevated in ABCs (194).
There is probably heterogeneity among ABCs in terms of relative responsiveness
to TLR7 versus TLR9 ligation; cells included by the surface marker criteria of Hao
et al show more extensive proliferation to TLR9 than to TL7 agonists, whereas
cells defined by the criteria of Rubtsov et al display the reverse. Whether this
reflects alternative routes of generation, different stages of the ABC
differentiation pathway, or other distinctions remains unclear.
ABCs are unusual – and again unlike other B cell subsets - because they
express both the BR3 and TACI receptors for BLyS but are independent of BLyS
for their survival (194). Thus, BLyS neutralization in vivo spares ABCs, despite
eliminating all FO and MZ B cells. Because ABCs display the same spectrum of
BLyS receptors as FO and MZ B cells, they bind and sequester BLyS
equivalently and can act as super-competitors for this limiting cytokine, inasmuch
as they consume BLyS but do not need it to survive. Accordingly, as ABCs are
generated and accumulate, they capture a progressively larger proportion of the
BLyS-dependent niche at the expense of the FO compartment. Moreover, this
capacity for BLyS-independent survival capacity is similar to what has been
reported for Bmem cells, although currently defined Bmem pools do not express
BR3 (263). Given the recent advances in delineating murine Bmem cell subsets
(121, 264), exploring potential heterogeneity within the ABC pool may elucidate
how ABCs fit into the broader immunological context.
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3.1.4 ABCs exhibit a characteristic set of effector attributes
The unique functional attributes of ABCs extend to virtually all B cell
effector mechanisms, including antigen presentation, cytokine secretion, kinetics
of PC differentiation, and isotype switching preferences. Several studies have
established that ABCs are effective APCs. Initial findings in vitro indicated that
ABCs can serve as APCs, in accord with their comparatively high levels of MHC
II, CD80, and CD86 (194). Further, ABC-mediated antigen presentation in vitro
tends to skew naïve CD4 T cells to a TH17 fate, although this was not exclusive
of other CD4 T cell cytokine profiles (194). More recent findings indicate that
ABCs are also potent APCs in vivo (261). When activated by either TLR7 or
TLR9 agonists, ABCs secrete a variety of cytokines, including IFNγ, IL-4, IL-6,
and IL-10.

Finally, upon activation, ABCs rapidly differentiate to antibody

secreting PCs and tend towards IgG2a/c class switching (137, 261), despite their
broad surface IgM and IgD expression (194). Given their propensity to become
antibody-secreting

cells,

ABCs

may

constitute

a

population

of

slowly

accumulating Bmem cells generated in response to nucleic acid containing
antigens.

While it is unclear whether isotype or costimulatory molecule

expression governs Bmem cell responses (119-121), most ABCs are unswitched
and remain uncharacterized for PD-L2 and CD73 expression. Lastly, ABCs also
express CD95 and CD138 based on microarray analysis (258), which are
markers associated with the GC and PC cell fates respectively (see Table 1).
Further characterization should distinguish the possibility of distinct ABC subsets
or an atypical state of activation. In toto, ABCs effector mechanisms seem to be
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largely normal, although skewed toward a type-I response.
3.1.5 ABCs are generated in response to intracellular infections
Early adoptive transfer studies revealed that FO B cells give rise to ABCs.
In these studies, CFSE labeled FO B cells were transferred to congenic hosts
and harvested 30 days afterwards, revealing that transferred cells which had
extensively proliferated had acquired the ABC phenotype (194).

This

observation linked the generation of ABCs with extensive division, although the
stimulating conditions driving the phenotype were unclear, and further functional
characterization of these recently formed ABCs was hampered by the small cell
numbers recovered in such experiments. Nonetheless, these findings suggest
that ABCs are likely an antigen-experienced pool.

Since B cell responses

against viruses result in a protective, T-BET dependent IgG2a/c response, it was
hypothesized that a viral infection would drive T-BET in vivo. Indeed, mice
infected with gamma herpes virus, vaccinia, or LCMV all produced TBET+CD11c+ B cells (137). Of the TLR agonists used, TLR7 stimulation is the
most effective at driving T-BET expression in the context of BCR and IFNγ
stimulation. Lastly, B cell intrinsic T-BET expression played a non-redundant role
in controlling viral and anti-viral IgG2a/c production. These findings have been
extended to human studies where a subset of B cells in HIV-viremic individuals
also display an ABC surface phenotype but are yet to be fully characterized for TBET and CD11c (265). In toto, these data support the notion that ABCs are
indeed antigen experience cells arising from immune responses characterized by
nucleic acid containing antigens in the context of proinflammatory cytokines.
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Given the similar nature of the antigens, nucleic acid containing self-antigens,
like viruses, can drive a similar ABC-like program.
3.1.6 ABCs are associated with humoral autoimmune and autoinflammatory
diseases
Beyond their initial identification in aged mice, ABCs prematurely
accumulate in a variety of autoimmune prone mouse strains. A considerable
ABC population accumulates as early as 6 months of age in mice lacking the
tyrosine kinase, Mer, as well as in NZB/WF1 animals (258). In accord with these
findings, ABCs constitute a higher proportion of total B cells in female RA
patients (258). Moreover, before their detailed characterization in mice, ABC-like
cells were also observed in common variable immunodeficient (212) and
Sjögren's syndrome patients (187). It is unclear if the CD21-/lo cells in these
individuals constitute a bona fide ABC population, since they were not
characterized for CD11c, T-BET, or other subsequently appreciated ABC
makers. In contrast, a more recent investigation of an early-onset Evan’s
syndrome patient exhibited premature senescence and an increased number of
CD11c+TBET+ B cells that correlated with antinuclear antibodies (211).
Interestingly, duplicating the tripeptidyl peptidase II (TPP2) frame shift mutation in
mice recapitulated both the disease and ABC phenotype. Thus, ABCs are
implicated in both human autoimmune syndromes and in murine models of
humoral autoimmunity. These finding prompt the question of how the
dichotomous roles of ABCs – providing beneficial and appropriate effector
functions during intracellular infection but also being associated with humoral
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autoimmunity – can be mechanistically reconciled.
3.1.7 Summary of findings
In light of IL-21’s novel TBET-inducing capacity described in the previous
chapter, we sought to investigate whether the proposed model of cytokine
interplay on TBET+ B cell fates also holds true for ABC phenotype, formation,
and presumed function. Thus, we hypothesized that ABCs would adopt a cell
surface phenotype most compatible with BMEM cells and accumulate into this
antigen-experienced pool. Further, adoptive transfer studies suggest that ABC
formation depends on MHCII antigen presentation and CD40 costimulation.
Consistent with these results, we find that ABCs are somatically mutated.
Although causal relationships between ABC formation and autoantibody
production have not been established, we also observe that aged mice have
increased serum IgG2c, and anti-dsDNA antibodies are primarily IgG2c. Finally,
TFH cells in aged mice produce less IL-4, comparable IL-21, and more IFNγ than
adult counterparts in response to alum immunization. The implications of this
skewed TFH cytokine profile and resulting effects on B cells are discussed.
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3.2 MATERIALS AND METHODS
Mice
I-ab-/- C57BL/6 mice were gift from Dr. Terri Laufer; Cd40-/- spleens were shipped
overnight from Dr. Mandy Ford’s mouse colony; CD45.1 and CD45.2 C57BL/6,
and NZBWF1/J mice were obtained from Jackson Laboratory. Aid−/− mice were
bred at the National Institute on Aging (NIA). All animal protocols were reviewed
and approved by the Animal Care and Use Committees at the NIA and the
University of Pennsylvania.
Adoptive transfers
CD23+ splenic B cells were enriched by positive selection using MACS bead
system (Miltenyi Biotec), subsequently labeled with CFSE (eBioscience)
according to manufacturer’s instructions, and 8 million were adoptively
transferred into congenic hosts.
Flow cytometry
The same FACS reagents listed in chapter 2 were used with the following
additions: CD45.1 (A20, BL), CD45.2 (104, BL), Fas/CD95 (clone Jo2).
Mutational Analyses
The following gating strategies were used for sorting: FO B cells, CD93 (AA4.1)CD43- B220+ CD21/35+ CD23+; MZ B cells as CD93 (AA4.1)- CD43- B220+
CD21/35+ CD23Lo; and ABCs as CD93 (AA4.1)- CD43- B220+ CD21/35- CD23-.
Cells were lysed in Trizol and RNA was prepared. cDNA was synthesized using
SuperScript III reverse transcriptase (Invitrogen). Immunoglobulin heavy (IgH)
chain variable, diverse, and joining (VDJ) genes, and kappa light (Igκ) chain VJ
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genes were amplified using Taq polymerase (TaKaRa, Clontech) with 5’
degenerate primers specific to the framework 1 region of V genes and 3’ primers
located in the IgM or Igκ constant regions as previously described. PCR products
were then cloned into the Strataclone TA cloning vector (Agilent Technologies)
and sequenced. Only sequences with unique VDJ or VJ joins were counted. The
sequences were blasted against the mouse Ig loci using IgBLAST from NCBI to
identify V, D, and J gene segment usage and mutations. Lisa M. Russell Knode
in the Gearhart lab at NIA performed these experiments.
Serum antibody titers and NP-specific ELISA
Same procedure as explained in chapter 2 except that ELISA plates were coated
with 10 µg/ml NP4-BSA, NP33-BSA (Biosearch Technologies).
Quantitative PCR analysis
Same procedure as explained in chapter 2.
Statistics
Student’s t-test was used to generate all P-values, * P <0.05, ** P <0.01, *** P
<0.001, **** P <0.0001. All error bars are S.E.M. based on biological replicates.
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3.3 RESULTS
3.3.1 ABCs are phenotypically heterogeneous and accumulate into BMEM
cell pools
Others and we previously established that ABCs are phenotypically
distinct from other mature subsets and hypothesized that ABCs are a pool of
antigen-experience, BMEM cells (194, 259, 261). However, ABCs were reported
to express CD95, which suggests a GC B cell phenotype. To interrogate this
point, we performed a phenotypic analysis on ABCs using a variety of B cell
activation surface markers.

We find that ABCs bifurcate for CD95 (Fas)

expression, stain highly for CD38, but are negative for PNA (similar results
obtained with GL7) (Figure 15A). As a control, we used mature naïve B cells
(FO and MZ) and GC B cells (background GCs from a young mouse). Thus, we
confirmed prior reports of elevated CD95 expression, but the lack of PNA and
GL7 suggests that ABCs are not bona fide GC B cells.

Further, CD38

expression is consistent with a BMEM cell phenotype since mature B and BMEM
cells express CD38 while GC B cells and PCs do not (266, 267). Overall, these
data not only reinforce the idea that ABCs are phenotypically heterogenous, but
also that they likely inhabit BMEM cell pools.
In defining ABCs, other groups employed different gating strategies that
included T-BET and CD11c. To assess how this phenotypic strategy differs from
our own, we added these criteria to our FACS parameters. We find that our
gating strategy encompasses T-BET+CD11c+ ABCs as described by Rubtsov et
al (258). Furthermore, T-BET and CD11c expression defines 3 distinct groups of
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ABCs: T-BET-CD11c-, T-BET+CD11-, and T-BET+CD11c+ (Figure 15B, left).
Thus, we asked whether T-BET and CD11c expression correlates with CD95,
CD38, or IgM. The data show that all T-BET+ ABC subsets express high levels
of CD95 and CD38 regardless of CD11c levels, whereas the T-BET- subset is
low to negative for both of these markers. Importantly, CD11c+ ABCs had the
lowest surface IgM expression, which is indicative of class switching (Figure
15B, far right). Overall, these data confirm that ABCs are phenotypically diverse
with respect to isotype and canonical B cell activation markers. Further, the
broad expression of surface IgM on ABCs previously reported can be attributed
to distinct BMEM cell subsets.
A hallmark of immunoscenece is the progressive accumulation of memory
T cells with age (268); however whether BMEM cells increase with age has not
been interrogated.

If ABCs are BMEM cells that slowly accumulate over the

lifetime of the host, we reasoned that the switched T-BET+CD11c+ ABCs would
be a significant part of the BMEM cell pool in aged mice. Using the phenotypic
criteria described above, we observed an increased frequency of T-BET+CD11c+
into the switched, splenic BMEM cell compartment using the gating strategy in
Figure 4A (Figure 15C).

Importantly, while the total number of BMEM cells

increases by 5-fold, we observed a 13- and 22-fold increase of T-BET+ and BET+CD11c+, respectively (Figure 15 C & D).

Thus, these switched, T-

BET+CD11c+ ABCs phenotypically resemble the IL-21 driven BMEM cells
described in the previous chapter.
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Figure 15. ABCs phenotypically resemble and accumulate into BMEM cell
pools. (A) Representative FACS plots for CD95, PNA, and CD38 stains on GC B,
FO B, MZ B, and ABCs from 24 month old mice. GC B cells defined as
FO
B
cells
defined
as
GL7+IgM-CD19+B220+CD138 -IgD-DUMP-;
+
lo
+
+
MZ
B
cells
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CD23 CD21/35 CD93 CD43 B220 CD19 ;
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+
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+
CD23 CD21/35 CD93 CD43 B220 CD19 ;
ABCs
(in
red)
defined
as
CD23loCD21/35loCD93 -CD43 -B220+CD19+. (B) FO B cells and ABCs from (A) were
further probed for T-BET and CD11c. n = 3 independent experiments with >3 mice
per group. (C) Representative T-BET and CD11c staining on BMEM cells from adult
and aged mice gated as in Figure 4C. (D) Enumeration of populations in (C) across
3 independent experiments with 12, 10, and 11 mice aged <6, 12-21, and 22-30
months, respecively.
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3.3.2 ABC formation requires MHCII and CD40 expression
We previously showed that ABC-like cells can arise from FO B cells
following extensive in vivo expansion in adoptive hosts 30 days after transfer
(194). In these experiments, the extensively divided cells downregulated CD23
and CD21/35 and thus resembled ABCs (Figure 15A). Reasoning that this is a
proxy for ABC formation, we next tested whether surrogates of cognate help are
critical for ABC formation. Thus, we transferred MHC class II (I-ab-/-), Cd40-/-, or
WT B cells into WT congenic recipients. A month later, we observe a population
of donor-derived (CD45.2) B cells (Figure 16A). Consistent with prior results,
CFSEhi cells represent the vast majority of transferred cells, whereas some B
cells had extensively divided (CFSElo) and are low for CD23 (Figure 16B, WT).
Moreover, these CFSElo B cells adopt an ABC phenotype, including expression
of T-BET and CD11c (Figure 16C, left panel). In contrast, both MHCII and
CD40 deficient B cells yielded fewer extensively divided cells (Figure 16B), and
among these there was negligible TBET expression (Figure 16C). These results
are consistent with the view that ABCs arise from B cells involved in TD immune
responses because both antigen-presenting capacity and CD40 costimulation
are required.
3.3.3 ABCs have undergone SHM and correlate with increased IgG2c
autoantibodies
The phenotypic similarity to IL-21 driven cell fates, accumulation into BMEM
cell pools, and requirement of cognate interactions to form suggests that ABCs
originate from GC reactions. If so, then the V genes of ABCs should contain
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increased frequencies of mutations compared to other subsets. In collaboration
with the Gearhart lab, we counted the number of mutations in VDJ and VJκ exons
amplified from sorted FO, MZ, and ABC B cell subsets, and compared the V, D,
and J sequences to their germline counterparts to identify mutations. Sequences
from ABCs had a significant, four-fold increase in mutations compared to FO
cells and a significant two-fold increase compared to MZ cells (Figure 17A). As
a control, V exons were sequenced from FO and MZ cells from young Aid-/- mice,
which do not undergo hypermutation.

The mutation frequency was

approximately 2x10-3 mutations per bp for Aid-/- cells, which represents the
background frequency of errors produced during cDNA synthesis and PCR
amplification. Thus, ABCs have undergone AID-mediated somatic mutation.
In addition to SHM, AID also mediates CSR. Since B cell intrinsic T-BET
expression fosters switching to IgG2c, we reasoned that the accumulation of TBET+ BMEM cells would correlate with increased serum IgG2c in aged mice.
Indeed, analysis of serum IgG subtypes reveals that serum IgG1 concentrations
remain unchanged between young and aged mice; however, IgG2c is nearly 10fold higher in aged mice (Figure 17B). Finally, the emergence of increased
serum anti-DNA autoantibodies titers is another well-documented hallmark of
immunosenescence (234).

Thus, we reasoned these autoantibodies in aged

mice would also be of the IgG2c isotype. Using the autoimmune prone mouse,
NZ(BxW)F1 as a positive control, we observe that most of the dsDNA reactive
antibodies are of the IgG2c rather than IgG1 isotype in aged mice, whereas young
mice served as negative controls for both isotypes (Figure 17C). Overall, these
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observations are consistent with the idea that ABCs are likely a population of
somatically mutated, class-switched, BMEM cells arising from interactions with IL21 and IFNγ producing TFH cells. However, there is no clear causal connection
between the increase of both T-BET+ ABCs and IgG2c autoantibodies.
3.3.4 TFH cells produce less IL4 and more IFNγ in aged mice
As discussed previously, TFH cells instruct antibody isotype determination
via cytokine production. Therefore, given the skewing towards IgG2c observed in
aged mice, we asked whether these TFH cells are skewed in their cytokine
production profile. We reasoned that TFH cells in aged mice would produce less
IL4 or more IL21 and/or IFNγ. Therefore, we immunized mice with NP-OVA
precipitated in aluminum salts, which drive a robust IgG1 antibody response
(although other isotypes are also produced) against the immunizing agent via the
production of IL-4 from TFH cells. Using the gating strategy shown in Figure 8A
& 11A, we sorted TFH cells from immunized mice. Consistent with prior aging
reports, we observed a substantial decrease of naïve, CD62L+ CD4 T cells in
aged mice compared to adults (Figure 18A). Next, we probed for IL-21, IL-4,
and IFNγ mRNA from sorted TFH cells. The data show that while IL-21 mRNA
levels remained similar between aged and adult mice, TFH cells in aged mice
produced far fewer IL-4 and substantially more IFNγ transcripts (Figure 18B).
These data suggest that the resulting antibody response would be skewed
towards IgG2c rather than IgG1 in aged mice; however, this prediction does not
hold true.

Instead, consistent with many prior reports, the humoral immune

response in aged mice is severely blunted. Using high (NP25, Figure 18C) and
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low (NP4, Figure 18D) substitution ratios of hapten-carrier conjugates, we can
detect low and high affinity antibodies, respectively.

Thus, while adult mice

produced affinity matured NP-reactive antibodies of both isotypes, aged mice
produced far fewer antibodies of all affinities and isotypes. Thus, even though
TFH cells produce equivalent amounts of IL-21 between young and aged mice,
reduced IL-4 production is not sufficient to drive IgG2c in aged mice as observed
in Il4-/- mice and HP infection (Figure 12C).
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3.4 DISCUSSION
Together these data suggest that ABCs constitute a pool of antigenexperienced, BMEM cells that tend to express TBET. Phenotypic analysis reveals
that ABCs are heterogeneous and accumulate into BMEM cell compartments.
Consistent with this idea, we used a proxy of ABC generation and determined
that their formation is dependent on both antigen presentation via MHCII and
costimulation through CD40.

Moreover, the marked increase of somatic

mutations in VDJ and VJκ exons further confirms that ABCs require T cell help for
their formation and may originate from GC reactions. Furthermore, consistent
with its role in class switching, T-BET expression in ABCs correlates with
increased total and anti-dsDNA IgG2c. Finally, cytokine profiling of TFH cells in
aged mice reveals that they lose the capacity to produce robust IL-4 but make
substantial IFNγ. However, the antigen-specific humoral response is significantly
reduced and not skewed towards the IgG2c isotype as the TFH cytokine profile
would suggest. Overall, these data suggest that ABCs constitute a pool of BMEM
cells and require IL-4-limited T cell help to form.
Phenotypic analysis of ABCs provides important clues about their
presumed function and origin. Using well-defined markers associated with GC B
and BMEM cell fates (Table I), we find that ABCs express CD95, but not PNA or
GL7 suggesting they are not GC B cells (Figure 15A).

Moreover, high

expression of CD38 is consistent with a BMEM cell phenotype, and CD95
expression has been previously reported on BMEM cells (269).
TBET+ ABCs uniformly express CD95.
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Importantly,

While we speculate that CD95

expression may functionally sensitize ABCs to FasL-mediated cell death, many
other survival factors may overcome this extrinsic apoptosis pathway (270).
Furthermore, initial ABC phenotypic analysis revealed that they bear broad
surface IgM expression (194).

Dividing them further by T-BET and CD11c

reveals that the TBET+CD11c+ subset is mostly negative for IgM (Figure 15B).
Although it is unclear whether this is due to a TD or TI response, the data
indicate these ABCs have undergone CSR. Consistent with this, T-BET+CD11c+
ABCs accumulate into the switched BMEM compartment (Figure 15C & 15D).
Overall, these phenotypic data support the notion that ABCs are a
heterogeneous population of BMEM cells. However, the origins and necessary
cellular interactions for ABC formation remain unclear.
When first described, ABCs were found to be sensitive to sub-lethal
ionizing radiation and did not rebound from aged progenitor B cells in the BM
(194). Moreover, ABC accumulation was proportional to a decrease in mature
FO B cells. Thus, ABCs were thought to originate from mature B cell pools.
Adoptive transfers of FO B cells into congenic hosts revealed that extensive
division was sufficient to generate an ABC phenotype (i.e. CD23-CD21/35-).
Positive staining for T-BET and CD11c further confirmed that these extensively
divided B cells phenotypically resemble ABCs (Figure 16C).

Importantly,

extensive division and T-BET staining were largely abrogated when B cells could
not present antigen or receive costimulation. In these cases, some cells did
divide likely reflecting homeostatic expansion. Assuming that this assay is a
proxy of ABC generation, these data indicate that cognate interactions between T
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and B cells are required for ABC formation. In addition to the mutational analysis
(Figure 17A), we further conclude that ABCs may originate from GC reactions.
However, recent reports highlight an important role for the extrafollicular
response in autoimmune etiology (271, 272). These responses also require IL21 and MHCII expression on B cells for SHM and disease progression (273,
274).

Therefore, since ABCs tend to accumulate more quickly in these

autoimmune mice, both the extrafollicular and GC responses must be considered
as sources of ABC generation. While the data presented here cannot distinguish
between the two possibilities, we suggest that ABCs are a product of cognate T
cell interactions with limited IL-4 and abundant IFNγ and IL-21.
A long-standing observation of age-related immune dysfunction is the
emergence of autoantibodies (234).

Although murine autoantibodies were

reported to be IgG (237), subtype analysis was never performed. Thus, it is
tempting to speculate that the increase in total and anti-dsDNA IgG2c antibodies
is due to T-BET+ ABC accumulation (Figure 17B & 17C); however, currently
these associations are purely correlative. While the tempo of ABC accumulation
dramatically increases in autoimmune prone mice, bone fide ABCs in otherwise
healthy aged mice are yet to be rigorously tested for overt self-reactivity.
Nonetheless, if ABCs constitute a BMEM cell pool of autoreactive specificities,
then it would also be worthwhile to investigate whether they maintain
autoantibody titers by feeding into the PC compartment.

Moreover, the

preferential accumulation of IgG2c autoantibodies is important because the type
of IgG generated has profound effects on subsequent antibody effector function.
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Indeed, while antigen-binding capacity is crucial, the heavy chain isotype
determines functionality via binding to FcγRs, which are expressed on a variety
of myeloid cells and enhance effector functions such as ADCC, phagocytosis,
and opsonization (14).

Moreover, FcγRs can be inhibitory or activating

depending on whether the cytoplasmic tail bears an ITIM or ITAM, respectively
(275). Importantly, IgG2c binds to all 3 activating and 1 inhibitory FcγRs whereas
IgG1 only binds to one of each (276). Therefore, the result that most anti-dsDNA
antibodies in aged mice are IgG2c (Figure 17C) suggests that myeloid cells
receive increasingly proinflammatory signals when DNA-IgG2c complexes
engage ITAM-bearing FcγRs receptors. Although the lack of standards makes
absolute quantification impossible, whether the nearly 10-fold increase of total
serum IgG2c in aged mice is significantly composed of autoreactive specificities is
an important future consideration (Figure 17B).
Overall, these data indicate that ABCs likely represent a pool of BMEM cells
resulting from cognate interactions with IFNγ or IL-21 producing T cells.
Because these cytokines may originate from TFH cells, we wanted to know
whether TFH cells in aged mice have a cytokine production profile that is
permissive to the ABC phenotype. Indeed, TFH cells from aged mice made less
IL-4 and equivalent IL-21 to adults (Figure 18B), and thus we reasoned that the
resulting NP-reactive antibodies would be IgG2c instead of IgG1 as we had
observed with HP infection in Il4-/- mice (Figure 12C). Unsurprisingly, the most
consistent result was a diminished antibody response both in terms of quantity
and affinity regardless of isotype (Figures 18C & 18D). While it is difficult to
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dissect cause and effect, there exist a number of possibilities.

We cannot

conclude that aged TFH cells are intrinsically incapable of producing IL-4, since
improper priming in the aged microenvironment could also explain these data.
Importantly, TFH cells require two independent antigen presentation events from
both a DC and B cell to adopt full effector status (87). Thus, currently it is
impossible to know whether the aged T cell itself, DC, or B cell explain the
decrease in IL-4 and robust IFNγ production. However, when used as APCs in
vitro, ABCs have been shown to aberrantly skew T cells (194); therefore, it is
tempting to speculate that ABCs may contribute to this shift in cytokine
production in vivo. Lastly, aged TFH cells made substantially more IFNγ than
adults. It is documented that anti-IFNγ treatment reinvigorates the aged humoral
response back to adult levels (277), thus we consider that excess IFNγ in aged
mice may hinder the GC response. Overall these data indicate that TFH cells in
aged mice have a skewed cytokine profile, but that does not correlate with
expected antibody isotype outcomes.
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4. PERSPECTIVE
ABCs impact a broad spectrum of immunological phenomena, including
protective immunity to some pathogen classes, immunosenescence, and
autoimmunity. In mice, ABCs constitute an accumulating population of B cells
with unique surface phenotype, signaling properties, and effector status. While
initially described in aged mice, phenotypically and transcriptionally identical cells
are observed in humoral autoimmunity and immune responses against
intracellular pathogens in both mice and humans. These observations lead us to
propose that ABCs are a memory B cell population, and that the signals and
interactions that yield ABCs in both normal and autoreactive humoral responses
are comparable; these consist of concomitant signals from the BCR, nucleic acid
sensing TLRs, and inflammatory cytokines. Thus, understanding how responses
to endogenous versus exogenous nucleic acid-bearing ligands are regulated in
order to maintain tolerance yet allow appropriate responses to pathogens should
yield insights relevant to both protective and autospecific humoral immunity.
Inasmuch as ABCs were first detected by virtue of their progressively
increasing representation with age, the question arises as to whether they
contribute to age-associated alterations in immune activity and immune
responsiveness. This seems likely based on their unique spectrum of activation
requirements, antigen presenting capacity, and effector cytokine profile, and
several recent findings support this notion.
First, recent studies suggest that ABCs may be instrumental in the
decreased B lymphopoiesis associated with age. Ratliffe et al assessed the
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proportion of ABCs in mice at different ages, and found that the degree of B
lymphopoiesis depression was proportional to ABC representation with age
(260). Moreover, they showed that ABCs are a potent source of TNFα, and that
this cytokine was in part responsible for inhibiting the survival of B lineage
precursors in vitro and in vivo. These observations, coupled with the ability of
ABCs to occupy homeostatic space to the detriment of preimmune FO B cells,
are particularly intriguing in light of reports that B lymphopoiesis and robust
humoral responses can be rejuvenated in aged individuals by B ablative regimes
(278-282).
Second, recent studies have revealed aspects of TFH generation that rely
on cognate B cell interactions differ in young and aged mice. For example,
several laboratories have shown that optimal IL-21 and IL-4 production among
dendritic cell-primed TFH cells only occurs following antigen presentation by B
cells (87, 283, 284). However, under in vivo immunization conditions that
normally foster this TFH profile, aged individuals fail to generate TFH cells with the
characteristic upregulation of IL-4 (210). While causal links have not yet been
forged, it is tempting to speculate that ABC antigen presentation may foster at
TFH cytokine profile that lacks IL-4. Alternatively, TFH cells generated in aged
individuals may intrinsically skew towards a cytokine profile lacking IL-4, which
might be instrumental in driving ABC generation.
Third, in addition to the decline of B lymphopoiesis and functional T cell
alternations, an increase in anti-dsDNA, anti-nuclear, and other autoantibodies
occurs in both mice and humans (234, 237, 285, 286). Indeed, ABC
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accumulation correlates with serum autoantibody levels, and ABCs isolated from
aged mice and stimulated with a TLR7 agonist produced anti-chromatin (258).
While not PCs, ABCs could constitute a pool of BMEM cells that feed a population
of autoantibody secreting PCs. Thus, while ABCs accumulation has a number of
correlative associations with B cell development, altered T cell functionality, and
autoantibody production, causality is yet to be established.
ABCs in aged, virally infected, and autoimmune-prone mice and humans
share a common triumvirate of stimuli for their origin: BCR signals, nucleic acid
sensor ligation, and a type-I inflammatory cytokine milieu. This commonality is
likely the link that connects beneficial and pathogenic ABC formation. In
particular, the role of endosomal nucleic acid sensors driven by BCR-acquired
antigens may prove the most important feature. Over the past decade the
contribution of nucleic acid sensing PRRs, particularly TLR7 and TLR9, to the
etiology of autoimmune disease have come to forefront.

Beginning with the

seminal observation that BCR delivered nucleic acid ligands have distinct
survival and proliferative potentials for B cells (287), it has become increasingly
apparent that TLR7 and TLR9 both promote and regulate the progression of
humoral autoimmunity. To test this idea, Shlomchik’s group bred SLE-prone
mice to either TLR7 or TLR9-deficient mice (208, 288). Because extra Tlr7 gene
copies results in an SLE-like disease (289), it was expected that TLR7 deficiency
would ameliorate disease in autoimmune-prone mice. While this hypothesis was
indeed validated, TLR9 deficiency unexpectedly exacerbated disease (206, 208).
This suggests not only a regulatory role for TLR9 but also differential disease
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outcomes based on whether autoreactive B cells can sense RNA or DNA
moieties. These ideas are further confounded by the fact that TLR9 deficiency in
other models of autoimmunity ameliorates disease (290). Though the mechanism
by which TLR9 limits while TLR7 promotes disease remains unclear, recent
findings suggest a role for type-I interferon signaling for disease etiology (291).
Whether ABC formation occurs in these models of autoimmunity and whether
TLR7 and TLR9 modulate ABC accumulation is yet to be established. Thus, the
signals from the BCR, nucleic acid sensing TLRs, and inflammatory cytokines –
while exactly those involved in appropriate ABC-mediated immunity – are exactly
those that, when dysregulated, foster humoral autoimmunity.
While the interplay of IL-4, IL-21, and IFNγ dictate the assumption of TBET+CD11c+ B cells in the context of TLR engagement, the functional
consequences of making such cells remains elusive. Our infection and aging
studies reveal that ABCs phenotypically resemble BMEM cells; however, bona fide
BMEM cell function is not shown. Adoptive transfers of T-BET+CD11c+ BMEM cells
from PR8 primed Il4-/-ifng-/- mice (Figure 9A) into naïve recipients followed by
lethal PR8 challenge would begin to address whether these cells are sufficient to
mediate protection. If the recipients survive, then ABC-like cells observed in viral
infection do indeed constitute a functional pool of BMEM cells.

Moreover,

challenge with a heterologous virus may also elucidate a non-redundant role for
these cells independent of high affinity antibody. Indeed, it is suggested that
BMEM cells are less somatically mutated than their PC counterparts and are thus
more promiscuous in their specificity. In this regard, the established PCs and
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antibodies are blind to escape variants. Thus, BMEM cells may be better suited to
protect the host against variants of the original infectious agent.
T-BET expression may also provide further clues about ABC function.
While T-BET’s role in fostering CSR to IgG2a/c is well-established in B cells, other
studies (133) and our data show that a substantial amount of PR8-specific IgG2c
is independent of T-BET (Figure 9C).

Thus, while B cell intrinsic T-BET

expression is necessary to control viremia (137), T-BET may be orchestrating
other key cellular programs independent of CSR to IgG2a/c. Indeed, T-BET has
been shown to drive many cellular processes including proper chemotaxis,
metabolism, maintenance, and homeostasis (111, 129, 131, 132, 292).

Our

transcriptionally analysis (Figure 3B) confirm T-BET’s pleiotropic effects since
many genes involved in trafficking and metabolism are affected by T-BET
deficiency in addition to those necessary for SHM and CSR. Thus, does T-BET
deficiency alter BMEM cell trafficking patterns or homeostatic maintenance? To
answer this question, Cd19Cre/+Tbx21f/f mice infected with PR8 would reveal
whether protective BMEM cells traffic properly to sites of infection without T-BET,
i.e. the lung. Moreover, establishing a pool of T-BET+ BMEM cell pool via PR8
infection in hCD20-TamCre x Tbx21f/f mice followed by tamoxifen-mediated
deletion of T-BET would address their maintenance requirements. Furthermore,
long-term studies could also assess whether T-BET+ BMEM cells are necessary
for the maintenance of PR8 specific PC numbers and antibody titers. In each
experiment, adoptive transfers BMEM cells from PR8 immune mice where T-BET
has been deleted into naïve recipients would be necessary to prove whether they
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are protective independent of pre-established antibody titers. Thus, while our
data establish a role for IL-21 in mediating this cell fate, more studies are
necessary to determine functionality.
These observations and future directions lead us to propose the model
depicted in Figure 19. In general, any nucleic acid containing antigen harbors the
capacity to drive an ABC phenotype. However, growing evidence suggests that T
cell derived proinflammatory cytokine signals, as well as cognate help, may be
required to engender a long-lived ABC fate. In this regard, an activated B cell
presenting viral peptides can efficiently receive all three signals required for
recruitment into long-lived effector subsets. In contrast, autoreactive B cells
binding nucleic acid containing self molecules, such as apoptotic debris or other
sources, while receiving BCR and TLR signals will fail to receive further cues for
survival, resulting in short-lived responses or death. However, inadvertent or
aberrant recruitment of such short-lived autoreactive cells into long-lived effectors
would thwart this peripheral tolerance system, and yield sustained autoantibody
and auto inflammation driven by IgG2a/c production. Multiple routes to such
dysregulation could be envisioned, including overabundance of autoantigen or
deficiencies in the molecules that mediate these regulatory circuits.
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Figure 19. Both beneficial and pathogenic ABCs arise via a common triad of
signals. Preimmune FO, MZ, and/or TR B cells bind, internalize and traffic antigens to endocytic compartments via the BCR. Pathogen degradation leads to viral
nucleic acids engaging TLR7 or TLR9. Processing and loading of viral peptides
onto MHCII molecules results in cognate CD4 T cell interactions and T cell derived
inflammatory cytokine secretion. The combination of these signals leads to T-BET+
memory and effectors, and to IgG2a/c isotype switching. Normally, B cells that internalize nucleic acid containing self-antigens fail to survive because they lack the
cognate T cell interactions and appropriate cytokine signals to further differentiate
and survive. However, inadvertent or aberrant receipt of these signals can afford
survival of these self-reactive cells and enable their recruitment into a long-lived
memory and effector ABC pool.
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